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1.Introduction 
 
1. 1 History 
 
Malaria is a clinically manifest and infection [1].  It causes attacks of fever [2]. 
The malaria pathogen circulates in the red blood cells [2].  
The parasites belong to the species Plasmodium [1]. Plasmodium is the latin 
term for bad air [1]. This term was extended at the infections with relatives of 
the family Plasmodiidae at the vertebrates [1]. 
The Plasmodia belong to the sporozoa [2]. They are cell parasites [2]. 
 
In the article of Wernsdorfer & Wernsdorfer 2010, it was stated that the 
transmission of the malaria from the humans will be assured through the diptera 
[1]. The diptera belongs to the species anopheles [1]. They hatch abundantly 
near surface water [1]. It´s important, that there is in the proximity a food source 
for the imagos [1]. It is believed that the infections of plasmodium exist since the 
development of mankind in Africa [1]. There are also species specific climatic 
differences among the plasmodium [1]. Thereby are different settlements from 
plasmodium [1]. For example Plasmodium falciparum and also Plasmodium 
ovale are in the tropical and subtropical region of Africa [1]. Compared with this 
exist Plasmodium vivax and Plasmodium malariae in the moderate latitudes and 
they could also exist at the edge of the arctic [1]. 
 
It is interesting that there are hints of malaria which are found in the Edwin 
Smith surgically papyrus at 1600 before Christ [3] and also from the Ebers 
Papyrus at 1550 before Christ [4].  
Hippocrates from Kos, approximately 400 before Christ, described as the first 
author the clinical symptoms of malaria [5]. He described the classical trias 
which involve fever, shivering and attack of sweating [1]. He also described the 
periodicity and the danger of the different forms of malaria [1]. Hippocrates from 
Kos distinguished the tertian malaria from the quartan malaria [2]. 
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Celsus proposed in the 1st century A.D. a classification for the manifestation of 
the Malaria tropica, quartana and tertian [1]. The positive effects of the cortex of 
Cinchona sp. in the treatment of malaria were found in the 17th century [1]. 
Interesting is the history of the use of Cinchona cortex [1]. There was a 
countess, called Chinchón [1]. She was the wife from the viceroy from Peru [1]. 
She got this cortex for the treatment of febrile diseases [1]. 
In the year 1640 this cortex was brought to Europe [1]. It was used for the 
treatment of malaria diseases [1].  
This tree got the name Cinchona from Linné [1]. He called the tree after the 
countess Cinchón [1]. Afterwards this cortex was called China-bark [1]. 
In the year 1820 Pelletier & Caventon undertook the extraction of the pure 
alcaloids [6]. 
There are four important alkaloids in this cortex [1]. The first one is Chinin with 
approximately 90 %, the second one is Chinidin with approximately 8 %, the 
third one is Cinchonin with 1 % and the last one is Cinchonidin with also 1 % 
[1]. Chinidin is an alkaloid with the highest clinical pathological effect against 
malaria [1]. 
A recommended dose was developed for the treatment of the different forms of 
malaria [1]. In the year 1890 Koch introduced the use of Chinin in hyperendemic 
regions of East Africa [1]. 
 
A big problem was the First World War [1]. It took a big part at the interruption of 
the supplies of chinin [1]. For example the Danube Monarchy, Germany and 
also the Turkey were split from the Chinin sources [1]. But also the opposition 
showed defects [1]. After the war there were synthetic malaria remedies 
developed [1]. In 1925 Pamaquin was a success [7]. It is an 8-Aminocholin and 
it is just a weak medicine [7]. But in 1930 another drug was found for the 
Chemoprophylaxis and also for the treatment of malaria [8]. The name of the 
drug is Mepacrin or  Atebrine [8]. 
 It was used until after the Second World War [1]. Chinin was less well-tolerated 
then Mepacrin [1].   
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It came through the Second World War to an intense research in the medicinal 
therapy and also in the combating of the vectors [1].  
 
In 1945 they were convinced in the malaria of primates that there must have 
been also an exoerythrocytic stage [9]. There were two researchers which 
found out, that there is at first a phase of division in the liver that the parasites 
could develop before invading the blood [10]. The names from the researcher 
were Henry Short and Cyril Garnham [10].  
Another important part in the second world war was 4-Aminochinoline 
(Chloroquin and Amodiaquin), and the 8-Aminochinolins Primaquin [1]. 
 Another point is that there were residual insecticids from the class of the 
chlorinated hydrocarbons developed [1]. Another problem is that resistance was 
also found against insecticides [1]. 
 
Another important part in the history took Golgi. In 1885 he discovered two 
parasites species [11]. He found them in the blood from peoples, which are 
infected with Tertiana and Quartana [11]. Afterwards they were known under 
the name Plasmodium vivax and Plasmodium malariae [12]. 
In 1922 Plasmodium ovale was found [13]. 
In the 1920´s and 1930´s there were in many reports from new species 
reported. For example about Plasmodium knowlesi [4, 14, 9]. 
 This parasite was found in a macaque [15]. Plasmodium knowlesi has a lethal 
effect for rhesus monkeys [15].  
There is an evidence that the Plasmodium knowlesi parasite is a zoonotic 
parasite [16, 9]. 
 
Another interesting way took the indanthrene processes [1].  
In the year 1890 Romanowsky developed an indanthrene processes with eosin 
and azure-methylene blue. This process made a differentiation of the blood 
cells possible. Another point is that you could perceive morphological specifics 
[17, 18].  
Afterwards other modifications were developed for example by Giemsa, 
Leishman, Field & Wright [1]. 
 10 
 
The path of infection took also an important part [1]. For example, in 1897 Ross 
observed the development from Plasmodium falciparum gametocytes in Culex, 
Aedes and also in Anopheles [1].  
 
 
1. 2 Distribution 
 
The risk of malaria was in the middle of the 19st century for approximately 90% 
[1]. The regions which were affected were parts of Europe and also of Siberia 
has been the arctic cycle affected [1]. Other regions were southern parts of 
Afrika, Southeast of Asia, Canada, Melanesia and also parts of South America 
[1]. 
The agriculture took also a big part in the control against malaria [1]. It came to 
a disappearance of malaria in many regions [1]. Some examples to this are 
England, Sweden, and parts of Denmark [1]. 
The WHO referred that this disease is now endemic in 106 countries [19]. There 
were 225 million cases and 781,000 deaths worldwide per year [19]. 
 
Mendis et al. wrote in an article of 2001 about malaria cases of P. vivax. For 
example there are over 50 % which are in the regions out of Africa. 
Approximately 65% of the these cases are in Southern Asia and also in the 
area of the Western Pacific [20, 24].  
It was stated that Plasmodium vivax appears in temperate zones and also in 
many tropical zones [55, 21]. Plasmodium vivax is very scarce in the region of 
the Western and Central Africa and of the region of sub-Saharan [22, 24]. 
The problem of this is that the merozoites of Plasmodium vivax just invade the 
erythrocytes of people which are Duffy-positive. But the Duffy-positive 
individuals occur very seldom in the regions of Africa [23, 24]. 
47 % of the malaria cases were in Thailand from the parasite Plasmodium vivax 
[25].  
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Sweden, England and also parts of Denmark are free of malaria [1]. The reason 
is that from the 19 century, there were many modifications in the agriculture [1]. 
The malaria was displaced also in the part of North America and also of Europe  
[1]. The reason about this was that the application of the mechanical methods 
about the vector control was high [1]. 
In the years 1945 and 1980 the malaria eradication was in some regions very 
high [1]. For example in Australia, Europe, USA and also big parts of North 
America and of Asia [1]. Nowadays the risk of malaria is 40% [1]. 
 
The malaria cases which are clinically manifest account annualy for 
approximately among 300 and 500 million [21]. In contrast to the clinically 
manifest malaria cases, the deaths have been lying per year among 1,1-2,7 
million [21].  
I should also like to add that these examples of malaria cases are mainly 
infections of Plasmodium falciparum [1]. 
In summary, it can be said that, the malaria cases in Africa belong to the 
highest, with a percentage of approximately 90 % [1]. The next countries are 
Asia and western area with roughly 10 % [1]. The malaria cases of the regions 
of America which are lying in the south of US are approximately 1% [1]. These 
clinically manifest malaria cases are mainly, with a percentage of 90 %, from 
the parasite Plasmodium falciparum [1]. The other one are from the parasite 
Plasmodium vivax [1]. It is important to say, that monoinfections of Plasmodium 
malariae and Plasmodium ovale are very rare [1]. 
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Fig. 1.2.1: Areas of the malaria transmission (WHO 2011) 
Source: http://www.fam.at/pdf/rel/FAM-Info_MalariaUpdate2011.pdf  
 (13.03.2012) 
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1. 3 The parasite and the clinical picture 
 
As mentioned at the beginning the malaria parasites belong to the subkingdom 
of Protozoa [1]. The phylum is called the Apicomplexa [1]. They belong to the 
class of the Sporozoasida [1]. The subclass where they belong are called 
Coccidiasina [1]. The order are the Eucoccidiorida [1]. The family are the 
Plasmodiidae and the genus was called Plasmodium [1]. The genus 
Plasmodium comprises to Garnham 10 subspecies [26, 1]. 
On that point belong P. (P.) with 20 primates-specific species. P. (Laveriana) 
with 2 primates-specific species. P. (Vinckeia) with 19 for lemurs and lower 
mammals specific species, P. (Haemamoeba), P. (Giovannolaia), P. (Novyella) 
and P. (Huffia) with 31 for birds specific species [26, 1]. Other ones which take 
part on this are, P. (Sauramoeba), P. (Carinamoeba) and P. (Ophidiella) with 40 
for reptiles specific species [26, 1]. 
To the subgenus P. (P.) and P. (Laverania) belong to 6 important species [1]. 
The species P. (L.) falciparum belong to the subgenus P. (Laverania) [27, 1]. 
This species is just a human pathogen [27, 1]. It is the phylogenetical youngest 
malaria parasite [27, 1].  
To the subgenus P. (P.) belong the 2 species P. (P.) vivax and P. (P.) ovale, 
which are a human pathogen [1]. P. (P.) malariae occurs in humans and also in 
primates [1]. P. (P.) cynomolgy and P. (P.) knowlesi belong to the monkeys and 
rarely in the humans [1]. 
It´s interesting that the Plasmodium knowlesi parasite only causes primate 
malaria [4]. In association with this, there are quotidian fever pattern [28]. In 
contrast to the Plasmodium knowlesi the merogony cycle of the parasite 
Plasmodium malariae continues 72 hours. The fever patterns at a Plasmodium 
malariae infection do not to be four days [29, 28]. 
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In the southeast of Asia there is a Plasmodium species, which is called P. ovale 
[1]. The role of this species is not yet resolved but we know that P. ovale shows 
a high stenoxenie for human beings [1]. Partially it was observed in humans [1]. 
The life treatening at the Plasmodium vivax malaria was very rarely, but this 
belief has now changed [30, 24]. The malaria tertiana is caused by the parasite 
Plasmodium vivax [24]. In relation to other forms of malaria, malaria tertiana is a 
harmless form of malaria [24]. The merozoites of Plasmodium vivax only infect 
the reticulocytes [24]. 
 
There are different symptoms which characterize the tertian malaria [24]: So the 
symptoms from the parties concerned are: 
a) recurrent fever, which is high [24] 
b)  shivering [24] 
c) anemia [24] 
d) arthralgia [24]   
One ather point in comparision with this, it is important to say, that the people 
could get also: 
a) cerebral malaria [31, 32, 33, 24]. 
b) liver dysfunction [31, 32, 33, 24]. 
c) severe anaemia [31, 32, 33, 24]. 
d) a respiratory distress syndrome, which is acute [31, 32, 33, 24]. 
e) a renal failure [31, 32, 33, 24] 
 
Plasmodium vivax and also Plasmodium ovale could  develop hypnozoites [2]. 
The problem is, that it could be leading to a relapse they are leading to relapses 
of the malaria[1]. Just the reticulocytes at Plasmodium vivax could be infected 
[34]. The densities of the limiting of the parasitaemia amounts under 100000/µl 
blood [34]. The hypnozoites have a span of survival, which could be five years 
[35, 34]. 
In relation to other Plasmodium species, which are pathogens for human 
beings, we could say that the incubation interval of Plasmodium vivax parasite 
is one of the shortest [36, 34]. In contrast to the Plasmodium vivax parasite, the 
Plasmodium falciparum parasite needs the erythrocyts for the survival [34]. 
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In contrast to the Plasmodium vivax infections, the Plasmodium falciparum 
infections have at first in the liver the pre-erythrocytic development and 
subsequently they are in the blood [37, 34]. 
There is a special definition for the malaria relapse, which I have seen in a 
article from Coatney in the year 1976. It predicates that: “re-appearance of 
parasitemia in a sporozoite-induced infection following adequate blood 
schizonticidal therapy” [38]. 
 
 
Tab. 1.3.1: The most malaria pathogens for the humans and their 
characteristics. 
 
 
Parameter 
P. 
falciparum 
P. vivax P. ovale 
P. 
malariae 
The afflicted 
erythrocytes 
All stages in 
the life 
reticulocytes reticulocytes 
older red 
blood cells 
The infected 
erythrocytes 
not enlarged enlarged enlarged 
not 
enlarged 
The multiple 
infested 
of the same 
erythrocytes 
often 
rarely 
(but it is often 
at Plasmodium 
vivax 
multinucleatum) 
rarely rarely 
The chromatin 
of the 
trophozoites 
often double rarely double simple Simple 
The Pigment brown/black 
yellow/brown, 
fine  
black, 
rugged 
black, 
rugged 
The number of 
the merozoites 
in the mature 
schizont 
24-36 16-24 8-12 6-8 
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The 
Gametocytes 
banana-
shaped 
round round round 
The time of the 
gametocytogony 
12 days 48-96 h 48-96 h 72-120 h 
The time of the 
erythrocytic 
schizogony 
48 h 48 h 48 h 72 h 
The number of 
the merozoites 
in the 
praerythrozytary 
schizonts 
20000-40000 10000 15000 2000 
The diameter of 
the 
praerythroytary 
schizonts 
60 µm 45 µm 70 µm 45 µm 
The ceiling of 
the parasitemia 
unlimited 150000 150000 
rarely 
>50000 
The maximum of 
the resting time 
from the 
infection in the 
human 
4 years 5 years 7 years life-long 
 
Source: Malaria (Wernsdorfer W. H. & Wernsdorfer G., 2010) 
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1. 4 The development cycle of Plasmodium 
 
The life cycle is, for example for the human malaria of all Plasmodium species 
the same [39]. So there is at first a sexual phase [39].  Such phase is followed 
by a part which was called sporogony [39]. These was in an anopheline 
mosquito [39]. Subsequently there is an asexual phase [39]. In this stage there 
is a erythrocytic and also a preerythrocytic part of schizogony [39]. 
The female anopheline mosquito injects the malaria sporozoites [39]. After the 
injection, the sporozoites walk on and leave the bloodstream in just a few 
minutes [40, 41, 39]. After 48 hours in the liver schizonts could be found [42, 
39].  
There are three phases which take an important part in the development cycle 
of Plasmodium. In the book of Wenk & Renz 2003, it was stated about the three 
phases, which I summarize in the following few pages. 
The first one is the phase of invasion: 
The sporozoites come through the prick of the insect into bloodstream [2]. It is 
assumed that they could also come through lymphatic cells [2]. 
The sporozoites stay in the peripherally blood for approximately 30 minutes [1]. 
At this time you could detect them [1]. They have achieved either the hepatic or 
they stay unspecific with an inactivation [1]. This point is related with 
phagocytosis in the blood [1]. 
 
The second phase is the hepatocytes-parasitic phase: 
On the first point, the sporocoits left the sinusoid capillary in the hepatic area 
[2]. They drift to the hepatocytic tissue [2]. They achieve the hepatocytic 
transgression across the Dissé-room [2]. The last host cell, which was infested 
builds a parasitophore vacuole [2]. This parasitophore vacuole will be formed 
around the meront [2]. But the sporozoits could drift also around the Kupffer 
cells to the parenchyma cells [2]. At this point the molecular docking 
mechanisms are important [2]. In the hepatocytes which are infected, there is 
schizogony [2]. After one week the meronts increase not longer, when P. vivax 
have 10 000 or P. malariae and also P. ovale have 15 000, or when P. 
falciparum have 30 000 merocoites [2]. 
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At P. vivax, P. ovale and P. Cynomolgi could be a part of the infected 
sporocoites, when they have achieved the hepatocytes, to convert to 
hypnocoites [1]. 
The hypnocoites make no proliferation [2]. Probably the reason is that they 
could be actived after a strain-specific diapause [2]. There are three 
consequences due to the unique limited schizogony: 
The first point is, when the merocoites are still in the hepatocytes, they don´t 
expose [2]. The second point is, that the surface of the hepatocytes is intact [2]. 
There are parasite-specific surface molecules. Interesting is that there is no 
inflammation [2]. A further point is that there are no granulomas established [2]. 
The third point is, that the incubation ends [2]. This happens when the transfer 
of the merocoites in the blood synchronizes [2]. It could be that they become in 
the hepatic-parasitic phase fever [2]. This stage is called prodromal period [2]. 
 
The next phase is called, the erythrocytic-parasitic phase [2]. There are many 
sporocoites which are at first in the liver and then they break now in the blood 
[2]. Subsequently they board the red blood-cells [2]. The merocoites build a 
mononuclear stage [2]. This stage is called the trophozoites [2]. It eats the 
substance from the red-blood-cells [2]. The shape from the trophocoites at 
Plasmodium vivax, Plasmodium ovale and Plasmodium malariae looks like an 
amoeba [2]. The shape of Plasmodium falciparum is at the beginning round, it is 
focal oblate and it has a nuclear which is marginal [2]. There is an orbital-phase 
[2]. This part circulates approximately 8 hours in the blood [2]. Subsequently 
this trophozoites take place in the capillaries from the following organs: The 
hepatic, the splenic, the brain and the placenta [2]. This is the reason, that you 
often couldn´t find the stages of division of Plasmodium falciparum [2]. But at 
the in vitro culture you could see all stages of the schizogony [2]. The meronts 
at the other Plasmodium of the humans stay in the circulated blood [2]. 
The first four stages of division are nearly free of symptoms [2]. One other 
important point is, that the parasitemia continues to rise [2]. So the density of 
the trophozoites increases in the blood [2]. When you sudden get at a 
Plasmodium falciparum infection with high fever, the letal flooding of the blood 
is confined [2]. The reason of this is, that the young trophozoites die, when the 
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body temperature is over 40°C [2]. When the latency of the humoral immune 
response is at the end, then there is a regulation of the density [2]. Whereby, 
this humoral immune response is from 6-8 days [2]. 
  When an infected human overcomes at the critical time, begins the 
maintenance of the parasitosis [2]. 
At the schizogony and the gamogony the trophozoites metabolize the 
haemoglobin [2]. This is important for Plasmodium, because it gets amino acids 
from the protein proportion [2]. It could make this with different proteases by 
hydrolyzing [2]. The haem is a complex of Porphyrin and Fe2+ [2]. It oxidized to 
ferriprotoporphyrin IX [2]. Subsequently it will be detoxified to a dimer 
indissoluble hemozoin. The hemozoin is a pigment of malaria [2]. 
The Plasmodium is also able to glycolyse to get energy [2]. The meronts which 
were burst released in the chronical phase of the malaria the antigens [2]. The 
antigens neutralize the antibodies [2]. So the antigens help the merozoites that 
they can come in the red blood cells before there is a humoral immune 
response [2]. 
All in all it is also important to say that a part of these parasites makes a 
preerythrocytic schizogony which continues for approximately 5 - 15 days [39]. 
This depends on the different species [39]. The mature schizonts are able to 
enlarge [39]. The mature schizonts busts and then the merozoites can come in 
the red blood cells [39]. Subsequently they initiate a schizogonic cycle [39]. The 
clinical manifestations are associated with this [39]. 
On the first stage of the infection the parasites will develop gametocytes in the 
humans [2]. 
When they come into the anopheles mosquito, they develop in the stomach 
microgametes and macrogametes [2]. 
In the ookinetes was done a development of the zygotes [39]. Then they drift 
through the stomach wall [39]. Then they form the oocysts [39]. This was done 
out of midgut [39]. Subsequently when the oocysts which are ready, bursts and 
then they liberates about thousands of the sporozoites [39]. They walk from the 
salivary glands and then they migrate to other human host cells who gets 
pricked by the mosquito [39] 
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Fig. 1.4.1: The life cycle of Plasmodium 
Source: http://hardinmd.lib.uiowa.edu/pictures22/cdc/PHIL_3405_lores.jpg 
 (13.03.2012) 
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1. 5 The vector 
 
In the article of Wernsdorfer & Wernsdorfer about Malaria, from the year 2010, 
they stated also about the vector. 
The subgenus of Plasmodum – Laverania and of Plasmodium – Plasmodium 
are among to the diptera from the genus of anopheles [1]. It is necessary to 
say, that just the female mosquitos can transmit the malaria parasite [1]. The 
reason is that only the female mosquitos take blood [1]. There are 
approximately 420 species of Anopheles mosquitos [1]. But only 29 of them can 
transmit malaria [1]. 
Interesting is also the way of life of them. The Anopheles mosquitos are 
nocturnal [1]. They take the bloodmeal in the time between the dusk and dawn 
[1]. Also the egg deposit ensued in the same time [1]. The development of the 
vector is the following: 
At first the development is dependent of the temperature [1]. For example in 
regions of the tropical lowland is the development just one week [1]. The 
larvaes hatch between 24-36 hours [1]. That is the first phase of the larvae [1]. 
To the fourth phase of the larvaes vanish approximately 4-5 days [1]. 
Afterwards the nymph is ready [1]. The evolved imago is ready in 24-48 hours 
[1]. Subsequently the imago breaks out from the nymph [1]. 
The development takes a longer time in other regions where the climate is 
cooler [1]. 
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Tab. 1.5.1: The 29 species of Anopheles which are singnificant vectors of 
malaria. 
 
 Species Incidence 
Robust malaria A. Arabiensis 
PATTON, 1905 
Tropical Africa, South 
West - Arabia 
 A. fluviatilis JAMES, 
1902 
South East Asia 
 A. funestus GILES, 
1900 
Tropical Africa 
 A. gambiae ss GILES, 
1902 
Tropical Africa 
 A. melas THEOBALD, 
1903 
Tropical Africa 
 A. minimus minimus 
THEOBALD, 1901 
South East Asia 
 A. sacharovi FAVRE, 
1903 
Europe, West-Asia 
Intermediate stability A. atroparvus VAN 
THIEL, 1927 
Mediterranean region 
 A. dirus BAISAS, 1936 South East Asia 
 A. quadrimaculatus 
SAY, 1824 
US 
 A. sergenti 
THEOBALD, 1907 
South West Asia 
 A. sundaicus 
RODENWALDT, 
1925 
Littoral South East Asia 
Instable malaria A. aconitus DÖNITZ, 
1902 
South East Asia 
 A. albimanus 
WIEDEMANN, 
1820 
Central- and South 
America 
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 A. annularis VAN DER 
WULP, 1884 
South East Asia 
 A. aquasalis CURRY, 
1932 
Central- and South 
America 
 A. culicifacies GILES, 
1901 
South Asia 
 A. darlingi ROOT, 
1926 
South America 
 A. farauti LAVERAN, 
1902 
The area of the western 
pacific 
 A. hyrcanus sinensis 
WIEDEMANN, 
1828 
South East Asia 
 A. labranchiae 
FALLERONI, 1926 
Europe  and West Asia 
 A. maculatus 
THEOBALD, 1901 
South East Asia 
 A. messeae 
FALLERONI, 1926 
Europe and West Asia 
 A. minimus flavirostris 
LUDLOW, 1914 
South East Asia 
 A. pharoensis 
THEOBALD, 1901 
North East Africa and 
Sahelian zone 
 A. philippinensis 
LUDLOW, 1902 
South East Asia  
 
 A. punctulatus 
DÖNITZ, 1902 
New Guinea 
 A. stephensi LISTON, 
1901 
South Asia western of 
Myanmar 
 A. superpictus 
GRASSI, 1899 
Europe, West Asia 
Source: Malaria (Wernsdorfer W. H. & Wernsdorfer G., 2010) 
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1. 6 The vector control and treatment 
 
The prevention is an important point in this unit [19].  
 
Such points were from the WHO 2010 stated, which I summarize. 
There are important aims of control of the vectors: 
For this point it is important to reduce their longevity [19].  Another point is to 
control the vector density [19].  
 
There are two interventions which are important for the vector control [19]. On 
the one hand it should give a long-lasting insecticide-treated mosquito net and 
on the other hand it should give an indoor residual spraying which takes an 
important part [19].  
 
The treatment with antimalarials is not only important. The exposure prophylaxis 
also takes an essential part. For example you should use repellents like 
icaridine and diethyltoluamide. 
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1. 7 Treatment with antimalarials 
 
One treatment is the primaquine therapy [24]. At this treatment there are also 
problems [24]. It is not good for humans which contraindicated in patients which 
have a glucose-6-phosphate dehydrogenase deficiency [24]. It is also a 
problem for humans which are younger than four years [24]. The last point is, 
that it is also not good for women which are pregnant [24]. 
In the WHO 2001 it was stated that the standard therapy for people which are 
infectet with Plasmodium vivax is Chloroquine [43].  
The highest risk of resistance was eastern part of the Indonesia and also Papua 
[44]. 
Other regions were Indonesia, Myanmar [45], and also South-East Asian 
regions [44].  
But it is also important to mention that there were found also resistances of 
Plasmodium falciparum against chloroquin [1]. The resistances occurred in the 
border regions of Thailand and Cambodia and also in Venezuela and Colombia 
[46, 47]. 
There were also found other resistences against chloroquine were in the region 
of Southeast Asia, of South Amerika and Africa [1]. Nowadays, Plasmodium 
falciparum shows just in Central America resistance against chloroquine [1].  
Chloroquine had just an effect against the different blood stages [2]. 
Pyronaridine is an alternative to chloroquine [24].  There is a study which shows 
a synergism of the antimalarial pyronaridine and the antimalarial retinol [24]. 
The study was done in Plasmodium vivax [24].  
In another interesting study there was found also a synergism in other 
antimalarials [34]. The drugs which were tested are mefloquin, chloroquine, and 
artemisinin of Plasmodium vivax [34]. The study was done in northwestern 
Thailand [34]. The results had shown that there was no significant difference at 
all the three drugs [34].  
The resistance pressure to antimalarials ascends [48]. As compaired with this, 
Plasmodium also makes single and a multiple-mutations [48].  It is important to 
say that they could make also point-mutations [48].  
 26 
 
A combination therapy with the drug artemisinin with other antimalarial-drugs is 
very helpful [49].  
 
In summary, it can be stated that the antimalarial chloroquine will be gladly 
taken in areas where it is effective [19]. But it is a problem in regions where 
Plasmodium vivax shows resistances against chloroquine [19]. The WHO 2010 
shows the regions which shows resistances. For example as Indonesia, at 
Myanmar, at Thailand, at Malaysia, at Brazil, at Solomon Islands, at Ethiopia, at 
Peru and the last one was at Papua New Guinea [19]. In such regions it could 
use an combination therapy with the drug artemisinin [19]. 
 
In contrast to the treatment of Plasmodium vivax, the treatment of Plasmodium 
falciparum is: 
In Central America the chloroquine therapy is effective [19]. Also the 
combination therapy with the drug artemisinin could be taken for a Plasmodium 
falciparum infection [19]. It is essential to say, that the antimalarial artemisinin 
and also his derviates should not be taken orally [19]. One reason to this is that 
an oral monotherapie of these derivates could lead to resistances [19]. 
Approximately 21 African countries use artesunate-amodiaquine [19]. A study 
has shown, that this countries were 6 with more than 10% of a treatment failure. 
So the treatment failure shows also a big problem in many countries [19]. 
As time passed, the pressure of resistance to the antimalarials shows a big 
problem [19]. 
 
 
 
 
 
 
 
 27 
 
2. Material and methods 
2. 1 Drugs: 
2. 1. 1 Artemisinin 
The plant Artemisia annua L. has been known for a very long time [50, 52]. For 
approximately more than 2000 years this plant took an important part in the 
traditional medicine in China [50, 52].  Artemisinin was at first in the 1970s 
isolated [50, 25]. 
As previously mentioned, this plant has been appropriated from the traditional 
medicine [51]. There was a team which investigated approximately for example 
2000 recipes [51]. They all were traditional herbs [51]. Interesting is that they 
found out, that there are 640 recipies which show an antimalarial activity [51]. 
They tested many recipies of these in a rodent malaria and they found out, that 
the extracts from this plant inhibit the parasite growth [51]. One important 
person of this team was Youyou Tu [51]. He make a neutral extract [51]. These 
one had a toxicity which was low [51]. Interesting is, that the antimalarial activity 
was improved [51]. 
This drug has saved the live from many humans. Since the late 1990s it was at 
the very front of the treatment against malaria [51]. 
The chemical structure of artemisinin is have the following elements: It is a 
sesquiterpene lactone [52]. These one have a peroxy group [52]. It is a good 
drug which will be introduced against malaria [52]. This drug has a low toxicity 
[52]. 
The antimalarial activity caused by the endoperoxide group [51].  
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Abb. 2. 1. 1. 1: Structural formulae of artemisinin 
Source: Preparation of molecularly imprinted polymers for artemisinin 
based on the surface of silica gel (Gong & Cao, 2011) 
 
 
2. 1. 2 Eurycoma longifolia 
 
Eurycoma longifolia Jack is the name of the tree [53]. It is an evergreen tree 
which is flowering and also slim [53].  
The tree exists in the jungle of Malaysia and also in Indonesia [53]. This tree 
could growth to 15 meters [53]. There is a variation of tree products, which 
found also an application in the folk medicine [53]. It was called Tongkat Ali and 
Pasak Bumi [53]. It could be used as antimalarial [53]. It has also anabolic 
properties and also antipyretic properties [53] 
There are also early studies [54] which reported that there´s a bioactivity-guided 
fraction [53]. Eurycoma longifolia has a activity which was potent antiplasmodial 
than chloroquine [53]. 
When the purifaction of this fraction is ready, there are three quassinoid 
constituents [53]. They are called, eurycomanone, 13α(21)-
epoxyeurycomanone and 13,21-dihydroeurycomanone [53]. 
There is a study of eurycoma longifolia [53]. It was tested at Plasmodium 
falciparum [53]. The results from this study are, that there´s a synergism 
between the quassinoids [53]. 
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Abb. 2.1.2.1: Structural formulae of the major quassinoids in the 
standardizided  
                 Eurycoma longifolia extract: 
  1 = eurycomanone 
  2 = 13,21 –dihydroeurycomanone 
  3 = 13α(21)-epoxyeurycomanone 
Source: Activitiy of Eurycoma longifolia root extract against Plasmodium 
 falciparum in  Vitro (Wernsdorfer et al., 2009) 
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2. 2 Testing 
 
For a testing from Plasmodium vivax it is better to make an in vitro test [55]. It is 
better, because you could have a look at the sensitivity [55]. This is an essential 
difference to the in vivo test [55].  
The young trophozoites could mature to the stage of the schizonts of two 
Plasmodium parasites which are called Plasmodium falciparum and 
Plasmodium vivax [55]. They could mature to the schizont stage [55]. But they 
must be incubated at a temperature of 37°C [55]. This is being done in a 
defibrinated blood supported [55]. These one is with glucose [55]. 
Subsequently a micro technique will be used. It is for testing of the sensitivity of 
a drug. For this point it will be taken a RPMI-1640 medium. Such medium could 
favoured the growth [56, 55]. 
It is important to say, that in Plasmodium vivax are different asexual forms of 
this parasite, which are very different [55]. So this could be a problem of the 
evaluation [55]. The reason of this is, that it is requiring a special attention [55]. 
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2. 2. 1 In vitro test: 
 
In the article of Wernsdorfer et al., from the year 2009, it was also stated the in 
vitro test, after which I would like to refer to. 
So for this test there are a few points important: 
You should take 200 µl blood [53]. For this point it is important to give it in 
sterile tube [53]. Such one should be a heparinized and also a capillary tube 
[53]. They were than diluted with an RPMI-1640 medium [53]. This mixture was 
taken in an incubator with a temperature of 37,5°C for a time of 3 hours [53]. 
 
For the test it should be noted the test series from well A-H [53]. In well A is no 
drug. It is for the control [53]. From B-H there was the extract of the antimalarial 
[53]. The concentration ascends from B-H [53]. 
 
When the incubation is ready, it is important that they closed the plates [53]. 
Then they were given in a container with a candle [53]. Subsequently they were 
given in an incubator [53]. They were placed in it for a time of 23,5 hours at a 
temperature of 37,5°C [53]. When the incubation is ready, the tests will be 
harvested [53]. Thereby the supernatant fluid from the wells will be decanted 
[53]. And then the thick films were prepared [53]. The result is that there were 8 
films on one slide [53]. At the end, it is important to give the films in a Giemsa 
solution for colouring [53]. 
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2. 2. 2 Evaluation of the tests: 
 
For the evaluation the slides were read with the microscope [53]. It is important 
that we have a magnification about 1000x [57]. 
But for the evaluation you should know the eight forms of parasites which are 
distinguishable [55]. 
The young trophozoite, the medium-grown trophozoite, the advanced 
trophozoite, the early pre-schizonts, the late pre-schizonts, the mature 
schizonts, the early gametozyte and the late gametozyte [55].  
In the article of Tasanor et al, was stated about the eight forms of parasites. 
They started with the young trophozoites [55]. The diameter of the young 
trophozoite is approximately 4 µm [55]. It is particularly important that the form 
of the trophozoites [55]. They can look like a chromatin with cytoplasm [55]. The 
chromatin could It can also linked with a ring of a vacuole [55]. With an essential 
relevance is also the pigment of the young trophozoites [55]. You can not see 
the pigment [55]. 
The next stage is the medium-grown trophozoite [55]. The diameter of the 
medium-grown trophozoite is approximately 4-8 µm and they have a single 
bead of nuclear chromatin [55]. In this stage the cytoplasma could be separate 
[55]. But it can be also linked in a ring with an amoeboid structure [55]. As 
compared to the young trophozoite, the pigment could be seen, but not always 
[55]. 
To the advanced trophozoite, here is the diameter bigger than 8 µm and they 
have a big chromatin [55]. At this time the cytoplasma looks like an irregular ring 
and it often has a big vacuole [55]. You could also see the pigment [55]. 
The early pre-schizonts have a chromatin with dots [55]. You can see to 7 
points [55]. The nuclear segments look like good defined [55]. And the 
characteristics of the form are, that it is  deep-stained and also ovoid or they 
could have also round forms [55]. In the early pre-schizonts the pigment could 
make an aggregation [55]. 
To the late pre-schizonts we could say, that they have nuclear segments which 
are defined [55]. In contrast to the early pre-schizonts, the cytoplasm is on the 
one hand looser and on the other hand it begins to make a condense [55]. This 
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process is around the nuclei [55]. One other important point is the aggregation 
of the pigment [55]. 
In the mature schizonts, the segmentation of the whole cytoplasm is now ready 
[55]. The chromatin bodies armed with cytoplasm [55]. In contrast to the other 
schizonts, the pigment granules are concentrated and they they could look like 
a single round mass [55]. Important for the mature schizonts is, that the 
merozoites varies between 12 and approximately 24 [55]. 
The diameter from the early gametocyte is approximately 5 µm [55]. The 
chromatin is now in the cytoplasm [55]. In the early gametocyte it is not a 
vacuole [55]. 
To the late gametocyte, it has a diameter from approximately 5µm, but it could 
be also bigger [55]. The chromatin is now a single mass and there is also no 
vacuole [55]. It is also important to say, that the pigment granules are spread 
[55]. 
 
 
The first plate is for the pre-incubation with a time about 0 hours [55].  
There are some criteria which are important for the pre-incubation plate [55]. 
The first one is, that the pre-schizont count should not be over 10 to 200 
parasites which are asexual [55]. Another exclusion criteria is when there are 
over 5 schizonts which are mature at the 200 parsites which are asexual [55]. 
The computer program which was taken was Excel.  
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2.3 Data analysis 
 
Subsequently a data analysis will be done [55]. You have a look at the stage 
composition prior and after the incubation [55]. It is essential to know that you 
should count in each film 200 parasites which are asexual [55]. 
 
In the analysis the counts from the parasites were multiplied with a specific 
multiplier [24]. The multiplier for the young trophozoits was 0,75 [24]. The 
multiplier for the medium-grown was 2,75 [24]. The same multiplier is taken for 
the advanced trophozoites [24]. The multiplier for the pre-schizonts was 4,5 and 
at last the multiplier for the advanced schizonts was 5,5 [24]. Subsequently you 
should add the results and so you get the individual Population Indicator [24]. 
 
There are three points which are important criteria for a valid test. The first one 
is, that the pre-incubation population indicator should be of approximately <400 
[24]. As compared to the pre-incubation plate, the post-incubation population 
indicator in well A should be 100 points bigger [24]. And the last one is that it 
should be a reduction of the following population indicators [24]. 
 
 
 
2.4 Log-probit analysis 
 
The results were analyzed with the log-probit method of Litchfield and Wilcoxon 
[58].  
This is important, because you could make afterwards an exact log probit 
regression which shows also the dose effect. 
The analysis where taken now and has been adopted for the computer [59]. 
Important results for the dose effect were for example the results of EC50, 
EC90 and EC99 which I will show at the results [55]. 
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2.5 Study region and patients 
 
The study region was in Mae Sot. There is a clinic where all the blood samples 
for this study were taken.  
The region Mae Sot lies at the border of the state of the province which was 
called Tak [24]. These region is near Myanmar [24]. 
The studies were done in the year 2010. 
 
For the studies were taken 47 patients. The origin of the infection country was 
at 31 of the patients in the region of Myanmar. For the rest of the patients, the 
origin of the infection country was in the region of Thailand. 
The residence country was for 26 of the patients in Myanmar and for all the 
other one in Thailand. 
There were 32 males and 15 females. The most of the patients were workers or 
farmers. There were also some students and forestry workers. 
Interesting is the number of days of symptoms, before they have started with 
the treatment. The most of the patients have started with the treatment after 
three to four days of fever. 
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3. Results 
 
In the studies of my diploma thesis there may be used 47 patients. In all the 
studies the number of isolates, which were taken, was 31, i. e. all isolates from 
the border region.  
In this study it was interesting to know the pharmacokinetic interaction between  
the 3 standardized formulations of eurycoma longifolia extracts.  
In the end of the studies, we would like to know if there is a synergism between 
the 3 standardized formulations of eurycoma longifolia extracts in combination 
with artemisinin. 
We used different forms of evaluations. One important point is the log-probit 
analysis. As mentioned already, this evaluation is essential for the dose effect 
of the different forms of eurycoma longifolia and of artemisinin. 
For the evaluation of the results it is important to know some essential points. 
One example is the heterogeneity which was ᵪ2. If the heterogeneity is <1,30 
then ᵪ2 is low. One other point is the correlation coefficient which is r. If it is 
>0,97 then r is relatively high. The next one is the slope function. This variable 
shows, if the regression is slow or fast. The conversion factor from the slope 
function is fs [58]. 
At the end we have a look at the synergism. So we have done a variance 
analysis.  
There is a book from Swaroop et al. It is from the year 1966 and they stated 
about the statistical methods. The term which was important at this is the 
probability that the difference is merely due to chance [60]. 
   t =   
x1 and x2 denoting the difference of the incidences, 2n the double of cases 
incorporated in the analysis, and v1 as well as v2 the variances between the 
two sets of figures [60]. 
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Drug conc. SMI%
3,0 20,17
10,0 43,19
30,0 59,31
100,0 74,92
300,0 86,59
1000,0 94,48
3000,0 97,51
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
3. 1 Artemisinin 
 
The valid results have shown the following values.  
The number of the isolates where it applies was 31. These isolates were 
suitable for the in vitro test. 
 
 
Tab. 3.1.1: The drug concentration in nmol/l of Artemisin and the 
 inhibition of the schizonts maturation (SMI)  
 in percent. 
 
 
 
 
 
 
 
 
 
It is clearly recognizable that from the drug concentration of 3 nmol/l to 3000 
nmol/l  a maturation inhibition of the schizonts from 20,17 % to 97,51 % was 
observed. 
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n = 30 S = 11,7893 2,1350
a = 3,8174 A = 2,6361 1,8661
b = 0,4031 K = 7 3,2116
r = 0,9971 N' = 120 4,0484
c² = 0,3481 R = 1000 6,6087
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
EC1
EC50
EC84
EC90
EC95
EC99
EC16
Tab. 3.1.2: The regression parameters1 for Artemisinin 
 
 
 
In the table 3.1.2 are the regressions parameters where you can see if the 
antimalarial have a slow or a fast effect. 
 
So the regression parameters show the following interesting results. One 
important point is the slope function which was 11,7893. The value of the 
correlation of regression was in this study, with an result of 0,9971 relatively 
high, because it was more than 0,97.  Another point is ᵪ2 where you can see the 
heterogeneity. In this study it was relatively low, because the result was 0,3481.   
The factor of the slope function was 2,1350. The factors of  EC´s shows the 
following values: The fEC– 50 was 1,8661, the fEC-90 was 3,2116, the fEC–95 
was 4,0484 and the fEC–99 was 6,6087.  
 
 
 
 
 
 
 
 
 
                                                          
1
 From Litchfield & Wilcoxon (1949): n= number of isolate; a= intercept of regression; b= slope 
of regression; r= correlation of regression; ᵪ
2
= heterogeneity; S= slope function; A= intermediate 
term for fS; K= number of drug concentrations; N´= number of points from EC 16 to EC84; R= 
factor of the highest compared to the lowest concentration tested; fs= factor of S; fEC= 
multiplication or division factor for obtainin 95 % confidential intervals of EC 
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EC Mean
95% Confidence Intervals
Lower                  Higher
0,0586 0,0089 0,3872
1,5947 0,8545 2,9759
18,8001 10,0744 35,0834
221,6402 118,7698 413,6097
451,8291 140,6855 1451,1054
1112,7533 274,8624 4504,8723
6033,2202 912,9270 39871,4745
EC1
EC50
EC84
EC90
EC95
EC99
EC16
Tab. 3.1.3: The mean EC levels for Artemisinin and the 95 %  
 confidential intervals 
 
 
 
 
 
 
 
 
 
 
In the table 3.1.3 you can see the different means of EC which show you the 
effective doses. The mean of the EC 50 was 18,8001, of the EC 90 was 
451,8291 and of the EC 99 was 6033,2202. The unit of the means of EC is 
nmol/ 
 
 
 
 
 
 
 
 
 
Fig. 3.1.1: The log-probit regression for Artemisinin 
From the means of the EC´s in the Fig. 3.1.1 the log-probit regression of the 
effective doses of Artemisinin are shown. 
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Drug conc. SMI%
3,0 28,67
10,0 45,03
30,0 57,72
100,0 69,43
300,0 82,26
1000,0 90,53
3000,0 94,59
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
3. 2 Eurycoma longifolia 1 
 
The valid results have shown the following values.  
The number of the isolates where it applies was 31. These isolates were 
suitable for the in vitro test. 
 
Tab. 3.2.1: The drug concentration in nmol/l of Eurycoma-1 and the 
 inhibition of the schizonts maturation (SMI) in percent. 
 
 
 
 
 
 
 
 
It is clearly recognizable that from the drug concentration of 3 nmol/l to 3000 
nmol/l  a maturation inhibition of the schizonts from 28,67 % to 94,59 % was 
observed. 
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n = 31 S = 23,6325 2,9939
a = 4,1132 A = 4,9173 2,0211
b = 0,3145 K = 7 4,9025
r = 0,9988 N' = 155 6,9682
c² = 0,1095 R = 1000 14,4586
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
EC1
EC50
EC84
EC90
EC95
EC99
EC16
Tab. 3.2.2: The regression parameters2 for Eurycoma-1 
 
 
 
 
 
 
 
 
In the table 3.2.2 are the regressions parameters where you can see if the 
antimalarial has a slow or a fast effect. 
So the regression parameters show the following interesting results. One 
important point is the slope function which was 23,6325. The value of the 
correlation of regression was in this study, with an result of 0,9988 relatively 
high, because it was more than 0,97.  Another point is ᵪ2 where you can see the 
heterogeneity. In this study it was relatively low, because the result was 0,1095.  
The factor of the slope function was 2,9939. The factors of  EC´s shows the 
following values: The fEC– 50 was 2,0211, the fEC-90 was 4,9025, the fEC–95 
was 6,9682 and the fEC–99 was 14,4586.  
 
 
 
 
 
 
 
 
 
 
 
                                                          
2
 From Litchfield & Wilcoxon (1949): n= number of isolate; a= intercept of regression; b= slope 
of regression; r= correlation of regression; ᵪ
2
= heterogeneity; S= slope function; A= intermediate 
term for fS; K= number of drug concentrations; N´= number of points from EC 16 to EC84; R= 
factor of the highest compared to the lowest concentration tested; fs= factor of S; fEC= 
multiplication or division factor for obtainin 95 % confidential intervals of EC 
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EC Mean
95% Confidence Intervals
Lower                  Higher
0,0103 0,0007 0,1486
0,7101 0,3513 1,4352
16,7812 8,3029 33,9169
396,5803 196,2170 801,5409
988,2038 201,5699 4844,7043
3137,6327 450,2788 21863,6507
27396,0087 1894,7884 396108,2335
EC1
EC50
EC84
EC90
EC95
EC99
EC16
Tab. 3.2.3: The mean EC levels for Eurycoma-1 with the 95 % confidential 
 intervals 
 
 
 
 
 
 
 
 
 
 
In the table 3.2.3 you can see the different means of EC which show you the 
effective doses. The mean of the EC 50 was 16,7812, of the EC 90 was 
988,2038 and of the EC 99 was 27396,0087. The unit of the means of EC is 
nmol/l. 
 
 
 
 
 
 
 
Fig. 3.2.1: The log-probit regressionfor eurycoma-1 
 
From the means of the EC´s it arose in the Fig. 3.2.1 the log-probit regression 
of the effective doses of the eurycoma longifolia 1 extract. 
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Drug conc. SMI%
3,0 30,90
10,0 47,68
30,0 62,14
100,0 72,81
300,0 81,96
1000,0 91,01
3000,0 95,13
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
3. 3 Eurycoma longifolia 2 
 
The valid results have shown the following values.  
The number of the isolates where it applies were 31. These isolates were 
suitable for the in vitro test. 
 
 
Tab. 3.3.1: The drug concentration in nmol/l of Eurycoma-2 and the 
 inhibition of the schizonts maturation (SMI) in percent. 
 
 
 
 
 
 
 
 
At the drug concentration of 3 nmol/l to 3000 nmol/l the maturation inhibition of 
the schizonts amounts to 30,90 % to 95,13 %. 
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n = 31 S = 25,8468 3,1885
a = 4,2102 A = 5,3884 2,0618
b = 0,3058 K = 7 5,3234
r = 0,9983 N' = 155 7,7333
c² = 0,1474 R = 1000 16,7669
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
EC1
EC50
EC84
EC90
EC95
EC99
EC16
Tab. 3.3.2: The regression parameters3 for Eurycoma-2 
 
 
 
 
 
 
 
 
The table 3.3.2 informs about the regression parameters where the antimalarial 
have properties are identifiable. 
The regression parameters show the following interesting results. One 
important point is the slope function which was 25,8468. The value of the 
correlation of regression was in this study with an result of 0,9983 relatively 
high, because it was more than 0,97. Another point is ᵪ2 where you can see the 
heterogeneity. In this study it was relatively low, because the result was 0,1474.  The 
factor of the slope function was 3,1885. The factors of EC´s shows the following 
values: The fEC– 50 was 2,0618, the fEC-90 was 5,3234, the fEC–95 was 7,7333 
and the fEC–99 was 16,7669.  
 
 
 
 
 
 
 
 
 
 
 
                                                          
3
 From Litchfield & Wilcoxon (1949): n= number of isolate; a= intercept of regression; b= slope 
of regression; r= correlation of regression; ᵪ
2
= heterogeneity; S= slope function; A= intermediate 
term for fS; K= number of drug concentrations; N´= number of points from EC 16 to EC84; R= 
factor of the highest compared to the lowest concentration tested; fs= factor of S; fEC= 
multiplication or division factor for obtainin 95 % confidential intervals of EC 
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EC Mean
95% Confidence Intervals
Lower                  Higher
0,0066 0,0004 0,1102
0,5120 0,2483 1,0556
13,2333 6,4183 27,2846
342,0396 165,8927 705,2212
874,6235 164,2994 4655,9276
2869,3704 371,0410 22189,6932
26639,3512 1588,8045 446659,7438
EC1
EC50
EC84
EC90
EC95
EC99
EC16
Tab. 3.3.3: The mean EC levels for Eurycoma-2 with the 95 % confidential 
 intervals 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the table 3.3.3 you can see the different means of EC which show the 
effective doses. The mean of the EC 50 was 13,2333, of the EC 90 was 
874,6235 and of the EC 99 was 26639,3512. The unit of the means of EC is 
nmol/l. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3.1: The log-probit regression for eurycoma longifolia 2 
 
From the means of the EC´s as shown in the Fig. 3.3.1 the log-probit regression 
of the effective doses of the eurycoma longifolia 2 extract are visible. 
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Drug conc. SMI%
3,0 28,63
10,0 48,17
30,0 62,73
100,0 74,07
300,0 83,61
1000,0 91,76
3000,0 95,39
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
3. 4 Eurycoma longifolia 3 
 
The valid results have shown the following values. 
The number of the isolates with valid results are 31. There isolates were utilized 
for the in vitro test. 
 
 
Tab. 3.4.1: The drug concentration in nmol/l of Eurycoma-3 and the  
 inhibition of the schizonts maturation (SMI) in percent. 
 
 
 
 
 
 
 
 
 
At the drug concentration of 3 nmol/l to 3000 nmol/l a maturation inhibition of 
the schizonts from 28,63 % to 95,39% was observed. 
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n = 31 S = 21,9787 3,2233
a = 4,1627 A = 4,5746 2,1569
b = 0,3218 K = 7 5,4995
r = 0,9971 N' = 124 7,9926
c² = 0,2810 R = 1000 17,3890
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
EC1
EC50
EC84
EC90
EC95
EC99
EC16
Tab. 3.4.2: The regression parameters4 for Eurycoma-3 
 
 
Table 3.4.2 informs about regression parameters. 
The regression parameters show the following interesting results. One 
important point is the slope function which was 21,9787. The value of the 
correlation of regression was in this study, with an result of  0,9971 relatively 
high, because it was more than 0,97. Another point is ᵪ2 were you can see the 
heterogeneity. In this study it was relatively low, because the result was 0,9971. 
The factor of the slope function was 3,2233. The factors of  EC´s shows the 
following values: The fEC– 50 was 2,1569, the fEC-90 was 5,4995, the fEC–95 
was 7,9926 and the fEC–99 was 17,3890.  
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
4
 From Litchfield & Wilcoxon (1949): n= number of isolate; a= intercept of regression; b= slope 
of regression; r= correlation of regression; ᵪ
2
= heterogeneity; S= slope function; A= intermediate 
term for fS; K= number of drug concentrations; N´= number of points from EC 16 to EC84; R= 
factor of the highest compared to the lowest concentration tested; fs= factor of S; fEC= 
multiplication or division factor for obtainin 95 % confidential intervals of EC 
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EC Mean
95% Confidence Intervals
Lower                  Higher
0,0098 0,0006 0,1702
0,6136 0,2845 1,3235
13,4869 6,2529 29,0897
296,4242 137,4315 639,3536
723,3245 131,5244 3977,9580
2236,5511 279,8263 17875,9519
18581,3021 1068,5650 323110,6955
EC1
EC50
EC84
EC90
EC95
EC99
EC16
Table 3.4.3: The mean EC levels for Eurycoma-3 with the 95 % confidential 
 intervals 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the table 3.4.3 you can see the different means of EC which show you the 
effective doses. The mean of the EC 50 was 13,4869, of the EC 90 was 
723,3245 and of the EC 99 was 18581,3021.The unit of the means of EC is 
nmol/l. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4.1: The log-probit regression for Eurycoma longifolia 3 extract 
 
From the means of the EC´s it arose in the Fig. 3.4.1 the log-probit regression 
of the effective doses of the eurycoma longifolia 3 extract are shown. 
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Drug conc. SMI%
3,0 30,21
10,0 46,22
30,0 57,47
100,0 67,37
300,0 74,80
1000,0 85,31
3000,0 89,32
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
3. 5 Eurycoma longifolia 1 - Artemisinin 
 
The valid results have shown the following values. 
The number of valid isolates was 31. These isolates were utilized for the in vitro 
test. 
 
 
Tab. 3.5.1: The drug concentration in nmol/l of Eurycoma longifolia 1 – 
  Artemisinin and the inhibition of the schizonts  
 maturation (SMI) in percent. 
 
 
 
 
 
 
 
 
 
At the drug concentration of 3 nmol/l to 3000 nmol/l a maturation inhibition of 
the schizonts from 30,21 % to 89,32 % was observed. 
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n = 31 S = 52,1117 5,5483
a = 4,2780 A = 12,0472 2,4099
b = 0,2516 K = 7 10,9673
r = 0,9962 N' = 155 19,3159
c² = 0,2787 R = 1000 61,6615
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
EC1
EC50
EC84
EC90
EC95
EC99
EC16
Tab. 3.5.2: The regression parameters5 for Eurycoma longifolia 1 
 - Artemisinin 
 
 
Table 3.5.2 refers to the regression parameters. 
The regression parameters show the following interesting results. One 
important point is the slope function which was 52,1117. The value of the 
correlation of regression was in this study with an result of 0,9962 relatively 
high, because it was more than 0,97. Another point is ᵪ2 were you can see the 
heterogeneity. In this study it was relatively low, because the result was 0,2787.  
The factor of the slope function was 5,5483. The factors of EC´s shows the 
following values: The fEC– 50 was 2,4099, the fEC-90 was 10,9673, the fEC–95 
was 19,3159 and the fEC–99 was 61,6615.  
 
 
 
 
 
 
 
 
 
 
 
                                                          
5
 From Litchfield & Wilcoxon (1949): n= number of isolate; a= intercept of regression; b= slope 
of regression; r= correlation of regression; ᵪ
2
= heterogeneity; S= slope function; A= intermediate 
term for fS; K= number of drug concentrations; N´= number of points from EC 16 to EC84; R= 
factor of the highest compared to the lowest concentration tested; fs= factor of S; fEC= 
multiplication or division factor for obtainin 95 % confidential intervals of EC 
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EC Mean
95% Confidence Intervals
Lower                  Higher
0,0017 0,0000 0,1048
0,3385 0,1404 0,8157
17,6378 7,3188 42,5058
919,1364 381,3959 2215,0520
2877,6518 262,3848 31560,0537
12196,9304 631,4437 235595,2145
183079,8239 2969,1115 11288973,7751
EC1
EC50
EC84
EC90
EC95
EC99
EC16
Tab. 3.5.3: The mean EC levels for  Eurycoma longifolia 1 – 
 Artemisinin with the 95 % confidential intervals 
 
 
 
 
 
 
 
 
 
 
 
 
In the table 3.5.3 you can see the different means of EC which show you the 
effective doses. The mean of the EC 50 was 17,6378, of the EC 90 was 
2877,6518 and of the EC 99 was 183079,8239. The unit of the means of EC is 
nmol/l. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5.1: The log-probit regression for Eurycoma longifolia 1 extract  
 - Artemisinin 
 
From the means of the EC´s it arose in the Fig. 3.5.1 the log-probit regression 
of the effective doses of the eurycoma longifolia 1 extract - artemisinin. 
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Drug conc. SMI%
3,0 32,41
10,0 51,07
30,0 64,79
100,0 74,67
300,0 83,03
1000,0 89,54
3000,0 92,48
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
3. 6 Eurycoma longifolia 2 - Artemisinin 
 
The valid results have shown the following values. 
The number of valid isolates was 31. This isolates were suitable for the in vitro 
test. 
 
 
Tab. 3.6.1: The drug concentration in nmol/l of Eurycoma-2  
 – Artemisinin and the resulting inhibition of  
 the schizonts maturation (SMI) in percent. 
  
 
 
 
 
 
 
 
 
At the drug concentration of 3 nmol/l to 3000 nmol/l a maturation inhibition of 
the schizonts from 32,41 % to 92,48 % was observed. 
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n = 31 S = 36,2030 4,1054
a = 4,3517 A = 7,7783 2,2223
b = 0,2771 K = 7 7,4048
r = 0,9926 N' = 155 11,7436
c² = 0,6031 R = 1000 30,3745
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
EC1
EC50
EC84
EC90
EC95
EC99
EC16
Tab. 3.6.2: The regression parameters6 for Eurycoma-2 - Artemisinin 
 
 
In table 3.6.2 are the regression parameters summarized. 
The regression parameters show the following interesting results. One 
important point is the slope function which was 36,2030. The value of the 
correlation of regression was in this study with an result of 0,9926 relatively 
high, because it was more than 0,97. Another point is ᵪ2 were you can see the 
heterogeneity. In this study it was relatively low, because the result was 0,6031.  
The factor of the slope function was 4,1054. The factors of EC´s shows the 
following values: The fEC– 50 was 2,2223, the fEC-90 was 7,4048, the fEC–95 
was 11,7436 and the fEC–99 was 30,3745. 
 
 
 
 
 
 
 
 
 
 
 
                                                          
6
 From Litchfield & Wilcoxon (1949): n= number of isolate; a= intercept of regression; b= slope 
of regression; r= correlation of regression; ᵪ
2
= heterogeneity; S= slope function; A= intermediate 
term for fS; K= number of drug concentrations; N´= number of points from EC 16 to EC84; R= 
factor of the highest compared to the lowest concentration tested; fs= factor of S; fEC= 
multiplication or division factor for obtainin 95 % confidential intervals of EC 
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EC Mean
95% Confidence Intervals
Lower                  Higher
0,0023 0,0001 0,0712
0,2866 0,1290 0,6370
10,3768 4,6693 23,0606
375,6715 169,0443 834,8646
1058,7630 142,9837 7839,9101
3928,4615 334,5185 46134,3932
45943,6076 1512,5712 1395514,5014
EC1
EC50
EC84
EC90
EC95
EC99
EC16
Tab. 3.6.3: The mean EC levels for Eurycoma-2 - Artemisinin  
 with  the 95 % confidential intervals 
 
 
 
 
 
 
 
 
 
 
 
 
In the table 3.6.3 you can see the different means of EC which show the 
effective doses. The mean of the EC 50 was 10,3768, of the EC 90 was 
1058,7630 and of the EC 99 was 45943,6076. The unit of the means of EC is 
nmol/l. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6.1: The log-probit regression for Eurycoma longifolia 2 extract 
 - Artemisinin 
From the means of the EC´s it arose in the Fig. 3.6.1 the log-probit regression 
of the effective doses of the eurycoma longifolia 3 extract – artemisinin are 
followed through. 
 55 
 
Drug conc. SMI%
3,0 32,73
10,0 52,66
30,0 65,70
100,0 73,19
300,0 81,45
1000,0 87,99
3000,0 90,74
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
3. 7 Eurycoma longifolia 3 - Artemisinin 
 
The valid results have shown the following results. 
The number of valid isolates was 31. This isolates were suitable for the in vitro 
test. 
 
 
Table 3.7.1: The drug concentration in nmol/l of Eurycoma longifolia 3  
– Artemisinin and the resulting inhibition of the  
schizonts maturation (SMI) in percent. 
  
 
 
 
 
 
 
 
At the drug concentration of 3 nmol/l to 3000 nmol/l a maturation inhibition of 
the schizonts from 32,73 % to 90,74 % has been observed. 
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n = 31 S = 49,8116 5,3366
a = 4,4210 A = 11,3852 2,3858
b = 0,2545 K = 7 10,4249
r = 0,9871 N' = 155 18,1136
c² = 0,9485 R = 1000 56,2722
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
EC1
EC50
EC84
EC90
EC95
EC99
EC16
Tab. 3.7.2: The regression parameters7 for Eurycoma longifolia 3 
  – Artemisinin 
 
 
In table 3.7.2 the regression parameter are listed. 
The regression parameters show the following interesting results. One 
important point is the slope function which was 49,8116. The value of the 
correlation of regression was 0,9871. It was relatively high, because the result 
was higher than 0,97. Another point is ᵪ2 were you can see the heterogeneity. In 
this study it was 0,9485. This was relatively low. The slope function was 
49,8116.  The factor of the slope function was 5,3366. The factors of EC´s 
shows the following values: The fEC– 50 was 2,3858, the fEC-90 was 10,4249, 
the fEC–95 was 18,1136 and the fEC–99 was 56,2722. 
  
 
 
 
 
 
 
 
 
 
 
                                                          
7
 From Litchfield & Wilcoxon (1949): n= number of isolate; a= intercept of regression; b= slope 
of regression; r= correlation of regression; ᵪ
2
= heterogeneity; S= slope function; A= intermediate 
term for fS; K= number of drug concentrations; N´= number of points from EC 16 to EC84; R= 
factor of the highest compared to the lowest concentration tested; fs= factor of S; fEC= 
multiplication or division factor for obtainin 95 % confidential intervals of EC 
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EC Mean
95% Confidence Intervals
Lower                  Higher
0,0010 0,0000 0,0586
0,1954 0,0819 0,4662
9,7330 4,0795 23,2214
484,8164 203,2054 1156,6963
1498,2211 143,7150 15618,8738
6246,3502 344,8432 113143,8500
90904,1172 1615,4359 5115373,7265
EC1
EC50
EC84
EC90
EC95
EC99
EC16
Tab. 3.7.3: The mean EC levels for Eurycoma longifolia 3  
 - Artemisinin with 95 % confidential intervals 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.7.3 refers to the different means of EC which based on the effective 
doses. The mean of the EC 50 was 9,7330, of the EC 90 was 1498,2211 and of 
the EC 99 was 90904,1172. The unit of the means of EC is nmol/l. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.7.1: The log-probit regression for eurycoma longifolia 3 
  - artemisinin 
From the means of the EC´s it arose in the Fig. 3.7.1 the log-probit regression 
of the effective doses of the eurycoma longifolia 3 – artemisinin are reproduced. 
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3. 8 Variance analysis of resulting data 
In the book from Swaroop et al. they wrote about statistical methods, which I 
needed for the evaluation [60]. Variance analysis was introduced since the 
mixture of the artemisinin and the parallel administered eurycomanon charges 
resulted in Plasmodium vivax always in a significantly lower antiplamodiual 
activity as compared to freshly prepared 0,5 artemisinin: 0,5 eurycomanon 
charges. This indicates that the artemisinin + eurycomanon charge prepared at 
the Institute of Specific Prophylaxis and Tropical Medicine, Medical University of 
Vienna, has lost part of its activity due to long contact between aremisinin and 
the eurycomanon. This was obviously due to unstable artemisinin in the 
mixture. At the same time, the comparison between the two formulations 
indicated synergism at the lower artemisinin and eurycoma charges [60]. 
The term is the probability that the difference is merely due to chance [60]. 
   t =   
x1 and x2 denoting the difference of the incidences, 2n the double of cases 
incorporated in the analysis, and v1 as well as v2 the variances between the 
two sets of figures [60]. 
 
Analysis 
 
EURY1 – ART at IC50 
Result: 91,9466  Degrees of Freedom 54 (= 2,6908 at p = 0,01) significant 
 synergism 
EURY2 – ART at IC50 
Result: 37,2177 Degrees of Freedom 56 (= 2,6952 at p = 0,01) significant  
 synergism 
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EURY3 – ART at IC50 
Result: 93,2021 Degrees of Freedom 52 (= 2,6864 at p = 0,01) significant 
 Synergism 
 
EURY1 – ART at IC90 
Result: 32,1322 Degrees of Freedom 52 (= 2,6864 at p = 0,1) significant 
 synergism 
EURY2 – ART at IC90 
Result: 41,3496 Degrees of Freedom 56 (= 2,6952 at p = 0,1) significant 
 synergism 
EURY3 – ART at IC90 
Result: 29,7526 Degrees of Freedom 52 (= 2,6864 at p = 0,1) significant 
 Synergism 
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4. Discussion 
 
In all the seven studies, which included the study of Artemisinin, of eurycoma 
longifolia 1, of eurycoma longifolia 2 , of eurycoma longifolia 3, of eurycoma 
longifolia 1 – artemisinin, of eurycoma longifolia 2 – artemisinin and of 
eurycoma longifolia 3 – artemisinin it was seen, that the drugs shows an effect 
against the malaria parasite Plasmodium vivax. 
But the real essential statement is, that we found out, that there is a significant 
synergism between eurycoma longifolia 1 – artemisinin at IC 50; eurycoma 
longifolia 2 – artemisinin at IC 50; eurycoma longifolia 3 – artemisinin at IC 50; 
eurycoma longifolia 1 – artemisinin at IC 90; eurycoma longifolia 2 – artemisinin 
at IC 90 and eurycoma longifolia 3 – artemisinin at IC 90. 
It was also observed that the effect of the straight combination acted more 
rapidly.  
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6. Appendix 
 
6. 1 Zusammenfassung / Abstract 
 
Zusammenfassung: 
Malaria ist eine klinisch manifeste Infektion und daher ist es von essentieller 
Bedeutung sowohl eine Kontrolle des Vektors zum einen und zum anderen 
ausreichende Behandlungsmöglichkeiten zu finden. 
Da man mit dem großen Problem der Resistenzentwicklung des Parasiten 
gegen die pharmakologischen Therapeutika zu kämpfen hat, ist es von 
Bedeutung dem so gut wie möglich durch die Forschung entgegenzuwirken. 
In dieser Studie soll die pharmakokinetische Interaktion zwischen Artemisinin 
und den 3 standardisierten Eurycoma longifolia Extrakten bei Plasmodium vivax 
herausgefunden werden. 
Mae Sot ist jenes Gebiet, wo diese Studien durchgeführt wurden. Dabei hatten 
wir 47 Patienten, welche teils in Myanmar und zum anderen Teil in Thailand 
infiziert wurden.  
Es wurde eine in vitro Prüfung durchgeführt.  
Mit Hilfe der log-probit Analyse kamen wir zu folgenden wichtigen EC Werten: 
Für Artemisinin erhielten wir für EC-50 den Wert 18,8001 nM, für EC-90 den 
Wert 451,8291 nM und für EC-99 den Wert 6033,2202 nM. 
Für Eurycoma longifolia 1 erhielten wir für EC-50 den Wert 16,7812 nM, für EC-
90 den Wert 988,2038 nM und für EC-99 den Wert 27396,0087 nM. 
Für Eurycoma longifolia 2 erhielten wir für EC-50 den Wert 13,2333 nM, für EC-
90 den Wert 874,6235 nM und für EC-99 den Wert 26639,3512 nM. 
Für Eurycoma longifolia 3 erhielten wir für EC-50 den Wert 13,4869 nM, für EC-
90 den Wert 723,3245 nM und für EC-99 den Wert 18581,3021 nM. 
Für Eurycoma longifolia 1 – Artemisinin erhielten wir für EC-50 den Wert  
17,6378 nM, für EC-90 den Wert 2877,6518 nM und für den Wert EC-99 den 
Wert 183079,8239 nM. 
Für Eurycoma longifolia 2 – Artemisinin erhielten wir für EC-50 den Wert 
10,3768, für EC-90 den Wert 1058,7630 nM und für den Wert 45943,6076 nM. 
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Für Eurycoma longifolia 3 – Artemisinin erhielten wir für EC-50 den Wert 9,7330 
nM, für EC-90 den Wert 1498,2211 nM und für EC-99 den Wert 90904,1172 
nM. 
Durch die anschließende Varianzanalyse konnte man einen Synergismus 
zwischen den Eurycoma longifolia Extrakten mit Artemisinin bei jeweils IC-50 
und bei IC-90 feststellen. 
 
 
Abstract 
Malaria is a clinically manifest infection and for this it is essential to make a 
control of the vector and a adequate treatment. 
Because a big problem of this is, that the resistance pressure against the 
pharmacologic therapeutic is big. So it is essential to make a good research. 
In this study I will show you the pharmacokinetic interaction between artemisinin 
and the 3 standardized formulations of eurycoma longifolia extracts at 
Plasmodium vivax. 
The study was realized in Mae Sot. There were 47 patients. They were infected 
at one part in Myanmar and at the other part in Thailand. 
In this study we have done a in vitro test. 
With the help of the log-probit analysis we got the following important EC 
values: 
For artemisinin the EC-50 was 18,8001 nM, the EC-90 was 451,8292 nM and 
the EC-99 was 6033,2202 nM. 
For eurycoma longifolia 1 the EC-50 was 16,7812 nM, the EC-90 was 988,2038 
nM and the EC-99 was 27396,0087 nM. 
For eurycoma longifolia 2 the EC-50 was 13,2333 nM, the EC-90 was 874,6235 
nM and the EC-99 was 26639,3512 nM. 
For eurycoma longifolia 3 the EC-50 was 13,4869 nM, the EC-90 was 723,3245 
nM and the EC-99 was 18581,3021 nM. 
For eurycoma longifolia 1 – artemisinin the EC-50 was 17,6378 nM, the EC-90 
was 2877,6518 nM and the EC-99 was 183079,8239 nM. 
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For eurycoma longifolia 2 – artemisinin the EC-50 was 10,3768 nM, the EC-90 
was 1058,7630 nM and the EC-99 was 45943,6076 nM. 
For eurycoma longifolia 3 – artemisinin the EC-50 was 9,7330 nM, the EC-90 
was 1498,2211 nM and the EC-99 was 90904,1172 nM. 
Through the following varianz analysis, we could saw a synergism between 
eurycoma longifolia extracts with artemisinin at IC-50 and the same at IC-90. 
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6. 2 Tables 
 
Tab. 1.3.1: The most malaria pathogens for the humans and their 
characteristics. 
Source: Malaria (Wernsdorfer W. H. & Wernsdorfer G., 2010) 
 
Tab. 1.5.1: The 29 species of Anopheles which are singnificant vectors of 
malaria. 
Source: Malaria (Wernsdorfer W. H. & Wernsdorfer G., 2010) 
 
Tab. 3.1.1: The drug concentration in nmol/l of Artemisin and the inhibition of 
the schizonts maturation (SMI) in percent. 
 
Tab. 3.1.2: The regression parameters for Artemisinin 
 
Tab. 3.1.3: The mean EC levels for Artemisinin and the 95 % confidential 
intervals 
 
Tab. 3.2.1: The drug concentration in nmol/l of Eurycoma-1 and the inhibition of 
the schizonts maturation (SMI) in percent. 
 
Tab. 3.2.2: The regression parameters for Eurycoma-1 
 
Tab. 3.2.3: The mean EC levels for Eurycoma-1 with the 95 % confidential 
intervals 
 
Table 3.3.1: The drug concentration in nmol/l of Eurycoma-2 and the inhibition 
of the schizonts maturation (SMI) in percent. 
 
Tab. 3.3.2: The regression parameters for Eurycoma-2 
 
Table 3.3.3: The mean EC levels for Eurycoma-2 with the 95 % confidential 
Intervals 
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Tab. 3.4.1: The drug concentration in nmol/l of Eurycoma-3 and the inhibition of 
the schizonts maturation (SMI) in percent. 
 
Tab. 3.4.2: The regression parameters for Eurycoma-3 
 
Tab. 3.4.3: The mean EC levels for Eurycoma-3 with the 95 % confidential 
intervals 
 
Tab. 3.5.1: The drug concentration in nmol/l of Eurycoma longifolia 1 – 
 Artemisinin and the inhibition of the schizonts maturation (SMI) in percent. 
 
Tab. 3.5.2: The regression parameters for Eurycoma longifolia 1- Artemisinin 
 
Tab. 3.5.3: The mean EC levels for  Eurycoma longifolia 1 –Artemisinin with the 
95 % confidential intervals 
 
Tab. 3.6.1: The drug concentration in nmol/l of Eurycoma-2 – Artemisinin and 
the resulting inhibition of the schizonts maturation (SMI) in percent. 
 
Tab. 3.6.2: The regression parameters for Eurycoma-2 – Artemisinin 
 
Tab. 3.6.3: The mean EC levels for Eurycoma-2 - Artemisinin with  the 95 % 
confidential intervals 
 
Tab. 3.7.1: The drug concentration in nmol/l of Eurycoma longifolia 3 – 
Artemisinin and the resulting inhibition of the schizonts maturation (SMI) in 
percent. 
 
Tab. 3.7.2: The regression parameters for Eurycoma longifolia 3 – Artemisinin 
 
Tab. 3.7.3: The mean EC levels for Eurycoma longifolia 3 - Artemisinin with 95 
% confidential intervals 
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6. 3 Figures 
 
Fig. 1.2.1: Areas of the malaria transmission (WHO 2011) 
Source: http://www.fam.at/pdf/rel/FAM-Info_MalariaUpdate2011.pdf  
 (13.03.2012) 
Fig. 1.4.1: The life cycle of Plasmodium 
Source: http://hardinmd.lib.uiowa.edu/pictures22/cdc/PHIL_3405_lores.jpg 
 (13.03.2012) 
Fig. 2. 1. 1. 1: Structural formulae of artemisinin 
Source: Preparation of molecularly imprinted polymers for artemisinin based on 
the surface of silica gel (Gong & Cao, 2011) 
 
Fig. 2.1.2.1: Structural formulae of the major quassinoids in the 
standardizided  
                 Eurycoma longifolia extract: 
  1 = eurycomanone 
  2 = 13,21 –dihydroeurycomanone 
  3 = 13α(21)-epoxyeurycomanone 
Source: Activitiy of Eurycoma longifolia root extract against Plasmodium 
 falciparum in  Vitro (Wernsdorfer et al., 2009) 
 
Fig. 3.1.1: The log-probit regression for Artemisinin 
 
Fig. 3.2.1: The log-probit regressionfor eurycoma-1 
 
Fig. 3.3.1: The log-probit regression for eurycoma longifolia 2  
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Fig. 3.4.1: The log-probit regression for Eurycoma longifolia 3  
 
Fig. 3.5.1: The log-probit regression for Eurycoma longifolia 1 extract - 
Artemisinin 
 
Fig. 3.6.1: The log-probit regression for Eurycoma longifolia 2 extract- 
Artemisinin 
 
Fig. 3.7.1: The log-probit regression for Eurycoma longifolia 3 - 
Artemisinin 
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6. 4 Forms 
 
- Probit calculus sheet for Artemisinin 
- Probit calculus sheet for Eurycoma 1 
- Probit calculus sheet for Eurycoma 2 
- Probit calculus sheet for Eurycoma 3 
- Probit calculus sheet for Eurycoma-1 – Artemisinin 
- Probit calculus sheet for Eurycoma-2 – Artemisnin 
- Probit calculus sheet for Eurycoma-3 – Artemisinin 
- VARIANCE ANALYSIS OF RESULTING DATA 
- Patients list 
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Study Area: Year: Drug:
MAE SOT 2010 ARTEMISININ PV
A B C D E F G H
Pat. 
No.:   
Control 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
0 3 10 30 100 300 1000 3000
1 100 97,44 84,54 78,25 81,83 45,74 28,68 9,8
7 100 78,93 49,59 37,19 0 0 0 0
10 100 81,37 79,05 41,21 25,84 14,9 0 0
11 100 86,41 81,15 58,26 25,7 18,73 10,16 0
12 100 98,43 53,24 17,88 5,7 0 0 0
14 100 90,73 63,64 36,9 29,41 4,81 0 0
15 100 61,39 55,56 32,86 24,76 7,25 0 0
16 100 98,46 65,16 49,68 34,84 22,95 11,37 3,47
19 100 88,56 51,2 32,58 12,5 7,18 0 0
22 100 95 65,12 52,32 36,46 22,44 14,88 0
23 100 74,41 59,65 45,67 25,98 8,76 2,95 0
24 100 88,44 60,99 42,21 26,73 16,72 0 0
25 100 84,72 66,31 47,99 42 20,02 7,42 3,84
26 100 74,76 60,86 47,37 35,63 29,69 0 0
27 100 75,08 64,58 50,25 39,86 38,04 28,36 15,44
28 100 66,56 31,35 26,85 3,22 0 0 0
29 100 77,49 66,84 27,59 23,29 13,42 1,39 0
30 100 85,08 55,86 49,59 42,66 10,48 8,63 0,74
31 100 91,57 69,26 68,74 40,47 18,42 1,45 0,13
33 100 83,14 36,86 25,59 0 0 0 0
34 100 78,58 56,56 39,67 27,45 4,98 0 0
35 100 76,18 36,03 28,55 15,73 0 0 0
36 100 66,61 60,03 40,46 28,29 12,66 0 0
37 100 64,09 43,54 40,07 16,06 0 0 0
38 100 82,31 57,42 49,26 34 36,55 20,02 16,95
40 100 84,65 57,46 46,06 16,9 7,61 4,65 0
41 100 40,14 35,68 10,79 7,76 0 0 0
43 100 72,41 65,55 62,2 49,36 40,83 25,52 24,4
46 100 70,1 35,66 15,56 0 0 0 0
47 100 81,99 35,5 19,03 0,02 0 0 0
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Study Area: Year: Drug:
MAE SOT 2010 ARTEMISININ PV
Drug conc. SMI%
3,0 20,17
10,0 43,19
30,0 59,31
100,0 74,92
300,0 86,59
1000,0 94,48
3000,0 97,51
n = 30 S = 11,7893 2,1350
a = 3,8174 A = 2,6361 1,8661
b = 0,4031 K = 7 3,2116
r = 0,9971 N' = 120 4,0484
c² = 0,3481 R = 1000 6,6087
EC Mean
95% Confidence Intervals
Lower                  Higher
0,0586 0,0089 0,3872
1,5947 0,8545 2,9759
18,8001 10,0744 35,0834
221,6402 118,7698 413,6097
451,8291 140,6855 1451,1054
1112,7533 274,8624 4504,8723
6033,2202 912,9270 39871,4745
© W. H. Wernsdorfer (April 1995)
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
EC1
EC50
EC84
EC90
EC95
EC99
EC16
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Study Area: Year: Drug:
MAE SOT 2010 PV-EURY-1
A B C D E F G H
Pat. 
No.:   
Control 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
0 3 10 30 100 300 1000 3000
1 100 82,24 65,38 55,86 49,1 15,31 4,83 1,52
7 100 68,65 56,92 43,65 20,77 10,38 7,31 5,75
10 100 81,14 64,91 42,72 33,84 23,72 6,38 1,72
11 100 83,93 69,81 56,01 25 15,42 19,97 12,32
12 100 63,26 50,26 34,14 24,61 10,75 5,55 2,87
14 100 65,03 55,33 35,25 31,56 20,36 4,23 0
15 100 68,22 49,56 39,97 31,15 16,39 4,04 0
16 100 71,91 55,77 21,56 30,88 20,31 11,13 6,1
19 100 72,16 37,61 31,34 23,62 11,08 4,37 1,72
22 100 70,04 48,31 39,21 21,29 14,98 7,78 4,04
23 100 72,41 57,26 33,58 25,64 22,34 12,21 6,67
24 100 59,31 46,56 38,14 32,4 16,58 10,2 6,28
25 100 106,05 83,18 62,19 47,64 32,7 16,45 8,28
26 100 75,54 67,54 47,08 36,46 19,38 15,69 12,76
27 100 88,13 73,29 52,67 30,71 19,58 11,42 6,66
28 100 72,72 52,1 40,74 35,06 13,58 9,88 7,79
29 100 62,59 45,47 38,79 31,49 23,68 14,61 9,08
30 100 67,07 47,56 36,31 14,36 7,45 2,17 0
31 100 72,12 44,6 36,89 27,4 17,79 10,44 6,73
33 100 58,63 44,07 37,11 20,23 15,72 9,28 5,48
34 100 69,39 46,39 41,31 34,09 19,12 5,21 1,92
35 100 58,37 47,49 37,8 29,31 19,74 9,69 4,76
36 100 70,56 62,63 46,37 37,37 22,18 12,9 7,5
37 100 71,15 46,07 40,33 35,41 11,97 5,08 2,16
35 100 66,38 56,78 46,31 31,56 19,55 5,32 1,45
38 100 68,23 54,73 47,18 30,18 15,83 6,48 2,65
40 100 61,87 39,37 32,65 24,69 13,85 9,74 6,84
41 100 65,56 53,17 43,23 34,01 23,63 11,53 5,63
43 100 73,38 66,67 60,51 44,18 20,36 10,4 5,37
46 100 64,07 52,15 36,57 23,37 15,1 11,45 8,68
47 100 81,27 63,06 55,15 30,41 21,13 17,7 14,83
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Study Area: Year: Drug:
MAE SOT 2010 PV-EURY-1
Drug conc. SMI%
3,0 28,67
10,0 45,03
30,0 57,72
100,0 69,43
300,0 82,26
1000,0 90,53
3000,0 94,59
n = 31 S = 23,6325 2,9939
a = 4,1132 A = 4,9173 2,0211
b = 0,3145 K = 7 4,9025
r = 0,9988 N' = 155 6,9682
c_ = 0,1095 R = 1000 14,4586
EC Mean
95% Confidence Intervals
Lower                  Higher
0,0103 0,0007 0,1486
0,7101 0,3513 1,4352
16,7812 8,3029 33,9169
396,5803 196,2170 801,5409
988,2038 201,5699 4844,7043
3137,6327 450,2788 21863,6507
27396,0087 1894,7884 396108,2335
© W. H. Wernsdorfer (April 1995)
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
EC1
EC50
EC84
EC90
EC95
EC99
EC16
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Study Area: Year: Drug:
MAE SOT 2010 PV-EURY-2
A B C D E F G H
Pat. 
No.:   
Control 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
0 3 10 30 100 300 1000 3000
1 100 68,51 49,85 39,1 28,66 18,81 11,49 7,07
7 100 66,78 44,3 30,2 16,95 9,23 6,71 4,88
10 100 60,11 58,05 56,55 44,57 41,01 16,1 6,32
11 100 52,22 46,84 33,51 19,25 9,56 5,25 2,88
12 100 65,99 52,86 30,3 28,96 10,44 3,87 1,43
14 100 70,65 38,81 28,52 14,93 10,45 5,31 2,65
15 100 68,35 60,13 43,54 32,15 20 8,86 3,42
16 100 81,21 57,1 44,62 32,57 14,92 9,9 6,56
19 100 75,82 59,55 40,3 21,04 18,21 5,67 1,77
22 100 79,45 62,64 45,83 41,1 24,53 14,07 8,07
23 100 71,56 45,87 25 23,28 19,61 7,91 3,79
24 100 69,68 50,06 34,84 32,58 21,64 9,16 3,88
25 100 73,96 43,52 35,07 19,68 15,16 5,32 1,87
26 100 71,9 57,93 37,75 26,51 18,73 8,79 4,13
27 100 65,12 47,2 40,12 25,85 19,15 3,78 0
28 100 70,37 53,19 44,82 38,44 18,61 6,5 2,27
29 100 63,94 49,12 32,79 24,62 15,58 7,91 4,08
30 100 66,51 48,48 40,19 14,04 8,61 2,39 0
31 100 68,12 37,96 29,47 20,3 10,55 8,83 7,39
33 100 66,28 49,59 24,74 21,59 13,07 5,48 2,3
34 100 72,38 56,5 37,4 27,16 19,68 7,83 3,78
35 100 65,76 55,83 41,32 24,19 10,17 4,84 2,3
36 100 59,48 44,56 30,05 28,5 17,93 7,56 3,78
37 100 71,25 62,24 39,65 26,7 15,01 9 5,35
35K 100 68,49 52,34 36,33 28,26 21,74 18,23 15,29
38 100 69,31 47,38 41,17 35,32 21,92 11,33 5,86
40 100 79,79 68,35 47,4 27,79 24,96 13,97 7,88
41 100 75,62 59,56 38,37 18,14 18,14 11,63 7,46
43 100 66,75 47,66 36,75 32,21 21,69 13,51 8,47
46 100 66,05 54,43 44,65 32,1 21,93 14,13 9,7
47 100 70,65 60,07 43,17 35,32 28,16 13,48 6,45
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Study Area: Year: Drug:
MAE SOT 2010 PV-EURY-2
Drug conc. SMI%
3,0 30,90
10,0 47,68
30,0 62,14
100,0 72,81
300,0 81,96
1000,0 91,01
3000,0 95,13
n = 31 S = 25,8468 3,1885
a = 4,2102 A = 5,3884 2,0618
b = 0,3058 K = 7 5,3234
r = 0,9983 N' = 155 7,7333
c² = 0,1474 R = 1000 16,7669
EC Mean
95% Confidence Intervals
Lower                  Higher
0,0066 0,0004 0,1102
0,5120 0,2483 1,0556
13,2333 6,4183 27,2846
342,0396 165,8927 705,2212
874,6235 164,2994 4655,9276
2869,3704 371,0410 22189,6932
26639,3512 1588,8045 446659,7438
© W. H. Wernsdorfer (April 1995)
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
EC1
EC50
EC84
EC90
EC95
EC99
EC16
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 80 
 
Study Area: Year: Drug:
MAE SOT 2010 PV-EURY-3
A B C D E F G H
Pat. 
No.:   
Control 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
0 3 10 30 100 300 1000 3000
1 100 108,7 39,78 31,35 20,17 18,09 14,92 12,3
7 100 79,39 46,67 28,28 21,21 6,87 0 0
10 100 77,53 57,87 44,72 37,42 24,38 6,07 1,51
11 100 81,52 65 46,36 41,52 28,64 12,88 5,79
12 100 49,22 37,66 31,67 16,55 12,13 2,28 0
14 100 69,18 50,39 37,9 25,12 13,41 6,01 2,69
15 100 67,09 53,7 37,37 21,94 13,65 5,87 2,52
16 100 65,2 47,9 28,76 17,5 12,79 9,62 7,24
19 100 66,57 44,43 31,88 19,04 10,44 5,08 2,47
22 100 69,97 52,27 34,92 28,64 18,16 11,87 7,76
23 100 70,4 47,09 32,46 22,17 13,37 8 4,79
24 100 69,3 46,5 36,79 26,94 13,99 7,9 4,46
25 100 77,07 63,2 50 41,39 32,77 18,68 10,65
26 100 76 41,91 30,43 24,52 15,13 10,96 7,93
27 100 79,17 67,16 41,39 36,32 30,31 13,48 5,95
28 100 74,13 59,51 45,28 28,46 9,83 4,01 1,64
29 100 67,31 47,66 44,64 33,24 16,21 11,81 8,6
30 100 77,46 65,9 40,03 22,4 16,62 4,34 0
31 100 68,47 42,14 33,98 16,84 12,04 6,22 3,21
33 100 57,63 50,34 34,8 20,63 16,23 10,45 6,73
34 100 59,31 51,35 38,73 26,59 12,75 6,99 3,83
35 100 71,5 61,43 46,68 24,69 9,46 7,49 5,93
36 100 81,49 53,95 35,58 25,39 16,64 11,05 7,34
37 100 73,92 60,66 36,21 21,46 10,88 3,43 0
35K 100 74,62 46,52 35,3 18,54 10,04 5,9 3,47
38 100 73,49 68,37 50,85 37,83 25,74 15,97 9,91
40 100 63,13 47,76 28,66 25,37 17,16 11,34 7,49
41 100 67,14 52,04 45,91 37,89 29,56 5,35 0,97
43 100 70,7 42,33 27,22 11,19 8,54 1,73 0
46 100 57,11 44,92 31,06 20,07 10,39 4,78 2,2
47 100 68,9 50,39 36,24 32,66 21,93 11,04 5,56
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Study Area: Year: Drug:
MAE SOT 2010 PV-EURY-3
Drug conc. SMI%
3,0 28,63
10,0 48,17
30,0 62,73
100,0 74,07
300,0 83,61
1000,0 91,76
3000,0 95,39
n = 31 S = 21,9787 3,2233
a = 4,1627 A = 4,5746 2,1569
b = 0,3218 K = 7 5,4995
r = 0,9971 N' = 124 7,9926
c² = 0,2810 R = 1000 17,3890
EC Mean
95% Confidence Intervals
Lower                  Higher
0,0098 0,0006 0,1702
0,6136 0,2845 1,3235
13,4869 6,2529 29,0897
296,4242 137,4315 639,3536
723,3245 131,5244 3977,9580
2236,5511 279,8263 17875,9519
18581,3021 1068,5650 323110,6955
© W. H. Wernsdorfer (April 1995)
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
EC1
EC50
EC84
EC90
EC95
EC99
EC16
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Study Area: Year: Drug:
MAE SOT 2010 PV-EURY-1-ART
A B C D E F G H
Pat. 
No.:   
Control 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
0 3 10 30 100 300 1000 3000
1 100 68,19 59,86 34,78 28,73 13,45 8,67 5,59
7 100 54,59 37,66 30,45 15,44 5,48 0 0
10 100 55,19 36,96 32,41 28,23 70,76 11,39 6,24
11 100 52,54 23,39 28,81 19,49 5,59 0 0
12 100 59,18 49,77 49,77 7,59 9,1 14,72 10
14 100 68,23 43,92 34,2 28,82 23,44 9,55 3,89
15 100 67,43 60,07 38,46 26,68 15,22 7,86 4,05
16 100 61,99 38,01 31,07 22,24 14,67 4,73 1,53
19 100 56,07 42,58 27,75 24,58 16,31 11,44 8,02
22 100 59,47 48,97 32,08 27,95 19,14 10,32 5,56
23 100 69,51 56,12 41,17 20,78 16,5 7,38 3,3
24 100 63,38 44,71 34,71 28,38 20,15 10,59 5,57
25 100 71,97 59,87 43,95 35,82 24,54 10,12 4,17
26 100 63,15 44,56 39,7 27,97 18,93 14,57 11,21
27 100 87,65 70,15 42,54 34,99 12,86 7,89 4,89
28 100 74,25 53,22 42,07 30,93 22,45 9,26 3,88
29 100 78,82 61,69 48,07 37,38 20,63 16,21 12,74
30 100 64,74 41,06 32,88 25,21 19,42 5,28 1,94
31 100 52,08 43,09 28,79 27,45 13,98 10,82 8,37
33 100 90,32 83,51 82,31 79,4 77,63 71,33 65,57
34 100 77,8 57,76 36,28 33,57 24,01 10,29 4,91
35 100 80,34 60 54,12 38,15 26,89 9,08 3,07
36 100 76,09 61,37 41,98 31,49 9,33 4,52 2,79
37 100 73,6 52,27 37,06 21,12 20,45 7,87 2,53
35 100 87,95 81,69 74,31 70,87 64,21 62,67 61,76
38 100 76,29 69,32 51,32 37,1 30,54 15,06 7,93
40 100 87,63 80,09 75,1 73,7 72,19 69,28 66,99
41 100 73,92 52,4 48,56 37,5 31,01 6,49 1,36
43 100 75 53,48 50,5 38,18 30,1 14,68 7,16
46 100 71,23 54,07 46,13 35,91 22,22 8,23 3,05
47 100 64,94 45,71 27,14 15,84 9,87 4,94 2,97
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Study Area: Year: Drug:
MAE SOT 2010 PV-EURY-1-ART
Drug conc. SMI%
3,0 30,21
10,0 46,22
30,0 57,47
100,0 67,37
300,0 74,80
1000,0 85,31
3000,0 89,32
n = 31 S = 52,1117 5,5483
a = 4,2780 A = 12,0472 2,4099
b = 0,2516 K = 7 10,9673
r = 0,9962 N' = 155 19,3159
c² = 0,2787 R = 1000 61,6615
EC Mean
95% Confidence Intervals
Lower                  Higher
0,0017 0,0000 0,1048
0,3385 0,1404 0,8157
17,6378 7,3188 42,5058
919,1364 381,3959 2215,0520
2877,6518 262,3848 31560,0537
12196,9304 631,4437 235595,2145
183079,8239 2969,1115 11288973,7751
© W. H. Wernsdorfer (April 1995)
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
EC1
EC50
EC84
EC90
EC95
EC99
EC16
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Study Area: Year: Drug:
MAE SOT 2010 PV-EURY-2-ART
A B C D E F G H
Pat. 
No.:   
Control 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
0 3 10 30 100 300 1000 3000
1 100 70,65 55,97 40,85 26,51 14,35 6,79 3,21
7 100 59,3 32,82 26,74 20,41 6,2 1,03 0
10 100 62,99 42,28 20,71 14,94 4,07 0 0
11 100 66,67 48,72 36,86 29,49 17,34 10,26 6,07
12 100 52,34 37,95 33,09 17,63 4,14 1,26 0
14 100 65,04 44,3 36,44 31,11 20 13,04 8,5
15 100 61,89 49,19 33,06 20,85 6,35 1,3 0
16 100 57,29 33,56 30,85 21,02 18,47 1,19 0
19 100 63,92 45,36 26,8 18,39 10,86 6,83 4,3
22 100 63,23 50,97 32,59 12,86 3,44 1,2 0
23 100 66,27 55,47 50 30,62 25,89 13,91 7,47
24 100 65,64 49,2 18,42 14,96 5,56 2,72 0
25 100 72,28 49,18 25,93 10,43 7 3,43 1,68
26 100 48,91 31,56 19,53 15,94 13,44 8,59 5,49
27 100 70,55 49,64 30,16 21,19 19,06 0 0
28 100 66,31 31,85 24,31 18 17,85 10,62 6,38
29 100 53,99 37,48 14,1 11,32 7,24 4,45 2,74
30 100 71 58,8 33,6 19,97 6,02 3,8 2,4
31 100 71,84 42,33 27,38 27,38 13,59 6,02 2,67
33 100 71 46,68 36,71 20,09 16,62 15,41 14,29
34 100 77,49 54,7 48,2 37,02 19,2 6,22 2,08
35 100 60,61 40,53 33,08 20,08 9,85 4,8 2,33
36 100 83,71 64,22 44,73 30,04 20,96 14,69 10,3
37 100 67,71 47,59 39,24 27,05 16,01 12,18 9,27
35 100 80,13 74,28 72,33 67,66 62,15 59,47 56,9
38 100 73,57 53,87 44,14 40,77 31,67 14,84 6,96
40 100 81,4 54,52 41,6 31,14 23,26 16,15 11,27
41 100 86,06 81,22 70,99 68,6 64,94 60,15 55,77
43 100 70,63 52,38 39,86 20,37 15,52 8,38 4,52
46 100 66,9 50,24 32,14 27,62 19,76 12,98 8,53
47 100 65,93 50,12 27,21 11,74 5,35 2,67 0
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Study Area: Year: Drug:
MAE SOT 2010 PV-EURY-2-ART
Drug conc. SMI%
3,0 32,41
10,0 51,07
30,0 64,79
100,0 74,67
300,0 83,03
1000,0 89,54
3000,0 92,48
n = 31 S = 36,2030 4,1054
a = 4,3517 A = 7,7783 2,2223
b = 0,2771 K = 7 7,4048
r = 0,9926 N' = 155 11,7436
c² = 0,6031 R = 1000 30,3745
EC Mean
95% Confidence Intervals
Lower                  Higher
0,0023 0,0001 0,0712
0,2866 0,1290 0,6370
10,3768 4,6693 23,0606
375,6715 169,0443 834,8646
1058,7630 142,9837 7839,9101
3928,4615 334,5185 46134,3932
45943,6076 1512,5712 1395514,5014
© W. H. Wernsdorfer (April 1995)
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
EC1
EC50
EC84
EC90
EC95
EC99
EC16
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Study Area: Year: Drug:
MAE SOT 2010 PV-EURY-3-ART
A B C D E F G H
Pat. 
No.:   
Control 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
Conc. 
SCHIZ
0 3 10 30 100 300 1000 3000
1 100 72,84 45,22 31,3 22,9 14,73 8,06 4,4
7 100 68,02 42,78 31,31 24,56 13,9 0 0
10 100 76,94 47,36 26,25 20 18,89 14,44 11,03
11 100 61,86 30,34 21,06 11,49 7,95 0 0
12 100 54,77 38,15 35,23 26,77 20,77 10,92 5,74
14 100 61,59 45,41 35,77 30,95 18,66 14,93 11,94
15 100 60,32 36,82 23,78 20,34 5,44 3,44 2,8
16 100 57,66 38,7 22,43 21,17 16,27 0 0
19 100 56,91 41,34 23,29 20,96 15,14 15,14 13
22 100 66,76 44,14 26,29 14,99 8,45 4,36 2,24
23 100 50,3 32,16 18,75 12,5 2,29 0 0
24 100 59,31 31,94 20 14,58 9,72 3,33 0
25 100 56,74 41,45 27,85 13,34 12,31 8,29 5,58
26 100 45,43 25,54 11,42 10,35 6,45 5,38 4,49
27 100 52,31 41,77 25,01 24,11 18,84 6,19 2,03
28 100 85,45 73,54 72,43 70,27 66,58 65,74 61,5
29 100 69,94 56,99 43,9 33,04 18,01 6,99 2,7
30 100 68,84 32,83 33,39 18,7 15,65 3,19 0
31 100 77,99 51,2 30,94 24,08 17,38 12,44 8,9
33 100 76,26 51,82 43,02 27,79 19,83 13,13 8,9
34 100 80,37 64,41 46,33 31,21 12,01 10,88 9,8
35 100 73,83 37,92 29,51 15,62 15,22 3,07 0
36 100 76,19 55,03 37,96 31,88 16,67 12,7 9,68
37 100 93,68 84,39 73,73 70,23 65,48 61,83 54,43
35 100 61,28 43,87 23,26 16,3 11 6,69 4,07
38 100 64,4 46,36 30,11 26,52 3,58 1,67 0
40 100 68,91 57,97 33,91 26,41 15,94 4,84 1,47
41 100 90,72 80,8 76,82 65,32 61,05 57,66 54,46
43 100 73,84 51,02 42,41 35,31 23,79 11,09 5,77
46 100 57,93 41,15 25,4 19,66 12,53 5,29 2,23
47 100 64,06 55,2 40,44 29,78 10,4 0,64 0
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Study Area: Year: Drug:
MAE SOT 2010 PV-EURY-3-ART
Drug conc. SMI%
3,0 32,73
10,0 52,66
30,0 65,70
100,0 73,19
300,0 81,45
1000,0 87,99
3000,0 90,74
n = 31 S = 49,8116 5,3366
a = 4,4210 A = 11,3852 2,3858
b = 0,2545 K = 7 10,4249
r = 0,9871 N' = 155 18,1136
c² = 0,9485 R = 1000 56,2722
EC Mean
95% Confidence Intervals
Lower                  Higher
0,0010 0,0000 0,0586
0,1954 0,0819 0,4662
9,7330 4,0795 23,2214
484,8164 203,2054 1156,6963
1498,2211 143,7150 15618,8738
6246,3502 344,8432 113143,8500
90904,1172 1615,4359 5115373,7265
© W. H. Wernsdorfer (April 1995)
fEC-50 = 
fS = 
fEC-90 = 
fEC-95 = 
fEC-99 = 
EC1
EC50
EC84
EC90
EC95
EC99
EC16
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VARIANCE ANALYSIS OF RESULTING DATA 
The term is the probability that the difference is merely due to chance [60]. 
   t =   
x1 and x2 denoting the difference of the incidences, 2n the double of cases 
incorporated in the analysis, and v1 as well as v2 the vatiances between the 
two sets of figures [60]. 
Analysis 
EURY1 – ART at IC50 
Result: 91,9466  Degrees of Freedom 54 (= 2,6908 at p = 0,01) significant 
 synergism 
EURY2 – ART at IC50 
Result: 37,2177 Degrees of Freedom 56 (= 2,6952 at p = 0,01) significant  
 synergism 
EURY3 – ART at IC50 
Result: 93,2021 Degrees of Freedom 52 (= 2,6864 at p = 0,01) significant 
 synergism 
 
EURY1 – ART at IC90 
Result: 32,1322 Degrees of Freedom 52 (= 2,6864 at p = 0,1) significant 
 Synergism 
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EURY2 – ART at IC90 
Result: 41,3496 Degrees of Freedom 56 (= 2,6952 at p = 0,1) significant 
 synergism 
EURY3 – ART at IC90 
Result: 29,7526 Degrees of Freedom 52 (= 2,6864 at p = 0,1) significant 
 Synergism 
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MAE SOT STUDIES 2010 
 
Plasmodium vivax  PATIENT RECORD FORM 
 
 
Date 
Pat. 
No. 
Pat. 
Reg. 
MC 
Sex Age Occupat. 
Residence 
Country 
Origin of 
Infection 
Country 
No. 
Days 
Sympt. 
Before 
Seek. 
Treatm. 
Comments 
28.06.2010 1 14 m 30 forestry 
worker 
Thailand Myanmar 3d. 
fever 
 
30.06.2010 2 102 m 32 forestry 
worker 
Thailand Myanmar 7d. 
fever 
 
 3 23 m 24 forestry 
worker 
Thailand Myanmar 2d. 
fever 
 
01.07.2010 4 107 w 34 farmer Myanmar Myanmar 4d. 
fever 
 
 5 108 m 22 forestry 
worker 
Myanmar Myanmar 2d. 
fever 
 
 6 52 m 35 monk Thailand Thailand 4d. 
fever 
 
02.07.2010 7 114 m 18 worker Thailand Myanmar 11d. 
fever 
 
 8 121 m 79 farmer Myanmar Myanmar 9d. 
fever 
 
 9 64 m 35 forestry 
worker 
Thailand Myanmar 7d. 
fever 
 
 10 66 m 32 teacher Thailand Thailand 3d. 
fever 
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05.07.2010 11 137 f 31 farmer Myanmar Myanmar 3d. 
fever 
 
 12 154 m 18 worker Thailand Thailand 4d. 
fever 
 
 13 161 f 44 worker Myanmar Myanmar 4d. 
fever 
 
06.07.2010 14 169 f 36 farmer Myanmar Myanmar 5d. 
fever 
40,3°C 
 15 172 f 10 student Myanmar Myanmar 3d. 
fever 
 
07.07.2010 16 176 f 14 student Thailand Myanmar 10d. 
fever 
 
08.07.2010 17 36 m 65 farmer Thailand Myanmar 8d. 
fever 
 
 18 186 m 13 student Myanmar Myanmar 3d. 
fever 
 
 19 197 m 25 forestry 
worker 
Myanmar Myanmar 3d. 
fever 
 
09.07.2010 20 211 m 78 monk Myanmar Myanmar 3d. 
fever 
 
12.07.2010 21 214 f 26 housewife Thailand Myanmar 7d. 
fever 
 
 22 215 f 21 worker Thailand Myanmar 3d. 
fever 
 
 23 216 m 24 worker Thailand Myanmar 20d. 
fever 
 
 24 109 f 38 worker Thailand Thailand 4d. 
fever 
 
 25 223 f 15 farmer Myanmar Myanmar 3d. 
fever 
 
 26 42 m 34 farmer Thailand Thailand 3d. 
fever 
 
 27 229 f 26 worker Thailand Myanmar 3d.  
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fever 
13.07.2010 28 46 m 17 student Thailand Thailand 4d. 
fever 
venously 
blood 
 29 238 f 24 farmer Thailand Thailand 3d. 
fever 
venously 
blood 
 30 239 m 15 student Thailand Thailand 4d. 
fever 
venously 
blood 
 31 119 m 16 worker Thailand Thailand 1d. 
fever 
 
14.07.2010 32 122 f 66 housewife Thailand Thailand 6d. 
fever 
 
15.07.2010 33 54 m 30 farmer Thailand Myanmar 3d. 
fever 
 
 34 266 m 16 farmer Thailand Thailand 4d. 
fever 
 
 35 270 m 24 worker Thailand Myanmar 3d. 
fever 
 
 36 136 m 29 forestry 
worker 
Thailand Thailand 3d. 
fever 
F medium 
19.07.2010 37 279 f 13 student Myanmar Myanmar 7d. 
fever 
 
21.07.2010 38 5 m 15 student Thailand Thailand 3d. 
fever 
 
 39 9 f 30 worker Myanmar Myanmar 1d. 
fever 
venously 
blood 
 40 11 m 39 laboratory Myanmar Myanmar 3d. 
fever 
 
22.07.2010 41 13 m 21 worker Myanmar Myanmar 4d. 
fever 
 
 42 16 m 35 worker Myanmar Myanmar 2d. 
fever 
 
23.07.2010 43 20 m 19 worker Myanmar Myanmar 3d. 
fever 
 
 93 
 
28.07.2010 44 26 m 56 soldier Thailand Thailand 4d. 
fever 
 
 45 50 m 13 student Thailand Myanmar 1d. 
fever 
 
 46 43 m 45 worker Thailand Thailand 2d. 
fever 
 
02.08.2010 47 82 m 24 farmer Thailand Thailand 3d. 
fever 
venously 
blood 
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6. 5 List of abbrevations 
a intercept of regression 
A intermediate term for fS  
A. Anopheles 
b slope of regression 
EC Effective concentration 
fS factor of S 
fEC multiplication or division factor for  
 obtainin 95 % confidential intervals 
 of EC 
K number of drug concentration 
n number of isolate 
N number of points from EC 16 to EC 84 
nM Nanomolar 
P. Plasmodium 
Pat. No. Patient number 
r correlation of regression 
R factor of the highest compared to the  
 lowest concentration tested 
S slope function 
WHO World Health Organization 
ᵪ2 heterogeneity 
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